{
  "list": [
    {
      "id": "chads2-score-for-atrial-fibrillation-stroke-risk",
      "title": "CHADS₂ Score for Atrial Fibrillation Stroke Risk",
      "subtitle": "Stroke risk in AFib"
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score",
      "subtitle": "Mortality estimate for Community Acquired Pneumonia"
    },
    {
      "id": "ransons-criteria-for-pancreatitis-mortality",
      "title": "Ranson's Criteria for Pancreatitis Mortality",
      "subtitle": "Mortality estimate for Pancreatitis"
    },
    {
      "id": "amoxicillin-pediatric-ear-nose-throat",
      "title": "Amoxicillin Pediatric - Ear, Nose, & Throat Infections",
      "subtitle": "Drug dose calculator"
    },
    {
      "id": "cha2ds2-vasc-score-for-stroke-risk",
      "title": "CHA₂DS₂-VASc Score for Stroke Risk",
      "subtitle": "Stroke risk in AFib, better than CHADS₂ score"
    },
    {
      "id": "glasgow-coma-scale",
      "title": "Glasgow Coma Scale",
      "subtitle": "Objective level of consciousness"
    },
    {
      "id": "apgar-score",
      "title": "Apgar Score",
      "subtitle": "Assesses Neonates 1 & 5 mins after birth"
    },
    {
      "id": "metabolic-syndrome-criteria-aha-nhlbi-2005",
      "title": "Metabolic Syndrome Criteria (AHA/NHLBI 2005)",
      "subtitle": "Diagnosis for Metabolic Syndrome"
    },
    {
      "id": "dvt-probability-wells-score-system",
      "title": "DVT Probability: Wells Score System",
      "subtitle": "Risk for DVT"
    },
    {
      "id": "tia-prognosis-risk-of-stroke-by-90-days-after-presentation",
      "title": "TIA Prognosis: Risk of Stroke by 90 Days After Presentation",
      "subtitle": "90-day Stroke risk after TIA"
    },
    {
      "id": "timi-risk-score-for-stemi",
      "title": "TIMI Risk Score for STEMI",
      "subtitle": "Mortality risk after STEMI"
    },
    {
      "id": "timi-risk-score-for-unstable-angina-nstemi",
      "title": "TIMI Risk Score for Unstable Angina/NSTEMI",
      "subtitle": "Mortality risk after Unstable Angina/NSTEMI"
    },
    {
      "id": "nih-stroke-score",
      "title": "NIH Stroke Score",
      "subtitle": "Quantifies stroke severity"
    },
    {
      "id": "bleeding-risk-on-warfarin-therapy-any-bleeding-complication",
      "title": "Bleeding Risk on Warfarin Therapy (Any Bleeding Complication)",
      "subtitle": "Bleeding risk from warfarin"
    },
    {
      "id": "abcd2-score-for-tia",
      "title": "ABCD² Score for TIA",
      "subtitle": "Risk of stroke after TIA"
    },
    {
      "id": "has-bled-score-for-major-bleeding-risk",
      "title": "HAS-BLED Score for Major Bleeding Risk",
      "subtitle": "Bleeding risk with AFib anticoagulation"
    },
    {
      "id": "cardiac-risk-index-aaa-surgery",
      "title": "Cardiac Risk Index for AAA Surgery",
      "subtitle": "Cardiac Complication risk in AAA surgery"
    },
    {
      "id": "cardiac-risk-index-abdominal-surgery",
      "title": "Cardiac Risk Index for Abdominal Surgery",
      "subtitle": "Cardiac Complication risk in abdominal surgery"
    },
    {
      "id": "cardiac-risk-index-non-aaa-vascular-surgery",
      "title": "Cardiac Risk Index for Non-AAA Vascular Surgery",
      "subtitle": "Cardiac Complication risk in non-ASS vascular surgery"
    },
    {
      "id": "jones-criteria-for-diagnosis-of-rheumatic-fever",
      "title": "Jones Criteria for Diagnosis of Rheumatic Fever",
      "subtitle": "Diagnose rheumatic fever"
    },
    {
      "id": "endocarditis-diagnostic-criteria-duke-criteria",
      "title": "Endocarditis Diagnostic Criteria - Duke Criteria",
      "subtitle": "Diagnose endocarditis"
    },
    {
      "id": "ottawa-ankle-rule-for-the-use-of-x-ray-in-ankle-injury",
      "title": "Ottawa Ankle Rule for the Use of X-Ray in Ankle Injury",
      "subtitle": "Rule out imaging in ankle injury"
    },
    {
      "id": "creatinine-clearance-measured",
      "title": "Creatinine Clearance (measured)",
      "subtitle": "Direct measure of renal function"
    },
    {
      "id": "body-mass-index-quetelet-index",
      "title": "Body Mass Index",
      "subtitle": "Calculate BMI"
    },
    {
      "id": "anion-gap",
      "title": "Anion Gap",
      "subtitle": "Evaluates states of metabolic acidosis"
    },
    {
      "id": "parkland-formula-for-burns",
      "title": "Parkland Formula for Burns",
      "subtitle": "Fluid requirements after burns"
    },
    {
      "id": "maintenance-fluid-calculation-for-children",
      "title": "Maintenance Fluid Calculation for Children",
      "subtitle": "Fluid maintenance for children"
    },
    {
      "id": "cardiac-output",
      "title": "Cardiac Output",
      "subtitle": "Assess cardiac output"
    },
    {
      "id": "pediatric-glasgow-coma-scale",
      "title": "Pediatric Glasgow Coma Scale",
      "subtitle": "Assess mental state of pediatric patients"
    },
    {
      "id": "bode-index-copd",
      "title": "BODE Index for COPD Survival Prediction",
      "subtitle": "Estimate COPD survival"
    },
    {
      "id": "pulmonary-embolism-wells-score",
      "title": "Pulmonary Embolism Wells Score",
      "subtitle": "Estimate risk of Pulmonary Embolism"
    },
    {
      "id": "heart-score-major-cardiac-events",
      "title": "HEART Score for Major Cardiac Events",
      "subtitle": "6 week risk of cardiac event"
    },
    {
      "id": "quick-sofa-score-sepsis",
      "title": "qSOFA Score for Sepsis",
      "subtitle": "In-hospital mortality in non-ICU patients with infections"
    },
    {
      "id": "child-pugh-score-cirrhosis-mortality",
      "title": "Child-Pugh Score for Cirrhosis Mortality",
      "subtitle": "Prognosis for cirrhosis, guides treatment"
    },
    {
      "id": "intracranial-bleeding-risk-thrombolytic-therapy-of-mi",
      "title": "Intracranial Bleeding Risk From Thrombolytic Therapy of MI",
      "subtitle": "Hemorrhage risk after tPA"
    },
    {
      "id": "killip-class-heart-failure",
      "title": "Killip Classification for Heart Failure",
      "subtitle": "Mortality risk for Acute Coronary Syndrome"
    },
    {
      "id": "mods-score-multiple-organ-dysfunction",
      "title": "MODS Score: Multiple Organ Dysfunction",
      "subtitle": "ICU/In-hospital Mortality risk and LOS for MODS patients"
    },
    {
      "id": "centor-score-strep-pharyngitis",
      "title": "Centor Score for Strep Pharyngitis (Modified McIsaac)",
      "subtitle": "Diagnosis and treatment of strep throat"
    },
    {
      "id": "perc-rule-pulmonary-embolism",
      "title": "PERC Rule for Pulmonary Embolism",
      "subtitle": "Rules out Pulmonary Embolism (<2%)"
    },
    {
      "id": "ada-diabetes-risk-calculator",
      "title": "ADA Diabetes Risk Calculator",
      "subtitle": "Estimates T2D Risk"
    },
    {
      "id": "fall-risk-elderly-hospitalized-patients",
      "title": "Fall Risk in Elderly Hospitalized Patients",
      "subtitle": "Estimates risk of falls for elderly inpatients"
    },
    {
      "id": "abc-score-massive-blood-transfusion",
      "title": "ABC Score for Massive Blood Transfusion",
      "subtitle": "Predicts need for massive transfusion in trauma patients"
    },
    {
      "id": "acute-gout-diagnosis-rule",
      "title": "Acute Gout Diagnosis Rule",
      "subtitle": "Diagnose acute gout"
    },
    {
      "id": "bishop-score-vaginal-delivery-labor",
      "title": "Bishop Score for Vaginal Delivery and Induction of Labor",
      "subtitle": "Likelihood of successful vaginal delivery"
    },
    {
      "id": "chalice-rule-child-head-injury",
      "title": "CHALICE Rule for Child Head Injury",
      "subtitle": "Clinically significant head injuries in pediatric patients"
    },
    {
      "id": "burch-wartofsky-point-scale-thyrotoxicosis",
      "title": "Burch-Wartofsky Point Scale for Thyrotoxicosis",
      "subtitle": "Determines likelihood of thyrotoxicosis"
    },
    {
      "id": "mmrc-dyspnea-scale",
      "title": "mMRC Dyspnea Scale",
      "subtitle": "Dyspnea severity"
    },
    {
      "id": "rule-of-sevens-lyme-meningitis",
      "title": "Rule of 7s for Lyme Meningitis",
      "subtitle": "Diagnosis of lyme meningitis"
    },
    {
      "id": "san-francisco-syncope-rule",
      "title": "San Francisco Syncope Rule",
      "subtitle": "Defines low risk syncope"
    },
    {
      "id": "pediatric-appendicitis-score",
      "title": "Pediatric Appendicitis Score",
      "subtitle": "Predicts appendicitis in pediatric patients"
    },
    {
      "id": "dragon-score-post-tpa-stroke-outcome",
      "title": "DRAGON Score for Post-TAP Stroke Outcome",
      "subtitle": "Calculate before tPA, predicts long term outcome"
    },
    {
      "id": "vancouver-chest-pain-rule",
      "title": "Vancouver Chest Pain Rule",
      "subtitle": "2 hr rule out for low risk chest pain"
    },
    {
      "id": "behcets-syndrome-diagnostic-criteria",
      "title": "Bechet's Syndrome Diagnostic Criteria",
      "subtitle": "Diagnose Bechet's syndrome"
    },
    {
      "id": "kawasaki-disease-diagnostic-criteria",
      "title": "Kawasaki Disease Diagnostic Criteria",
      "subtitle": "Diagnose Kawasaki Disease"
    },
    {
      "id": "irritable-bowel-syndrome-diagnostic-criteria-manning",
      "title": "Irritable Bowel Syndrome Diagnostic Criteria (Manning Criteria)",
      "subtitle": "Diagnose IBS"
    },
    {
      "id": "multiple-myeloma-diagnostic-criteria",
      "title": "Multiple Myeloma Diagnostic Criteria",
      "subtitle": "Diagnose multiple myeloma"
    },
    {
      "id": "bacterial-meningitis-score-children",
      "title": "Bacterial Meningitis Score for Children",
      "subtitle": "Likelihood of bacterial meningitis in pediatric patients"
    },
    {
      "id": "ottawa-foot-rule-for-the-use-of-x-ray-in-foot-injury",
      "title": "Ottawa Foot Rule for the Use of X-Ray in Foot Injury",
      "subtitle": "Rule out imaging in foot injury"
    },
    {
      "id": "ottawa-knee-rule-x-ray-knee-injury",
      "title": "Ottawa Knee Rule for use of X-Ray in Knee Injury",
      "subtitle": "Rule out imaging in knee injury"
    },
    {
      "id": "rockall-score-upper-gi-bleeding",
      "title": "Rockall Score for Upper GI Bleeding",
      "subtitle": "Determines severity of GI bleeding"
    },
    {
      "id": "aims65-score-upper-gi-bleeding",
      "title": "AIMS65 Score for Upper GI Bleeding Mortality",
      "subtitle": "Determines in-hospital mortality from upper GI bleeding"
    },
    {
      "id": "lower-gi-bleeding-risk-severe-bleeding",
      "title": "Lower GI Bleeding and Risk of Severe Bleeding",
      "subtitle": "Evaluates severe bleeding risk"
    },
    {
      "id": "pancreatitis-prognosis-criteria-disease-gallstones",
      "title": "Pancreatitis Prognosis Criteria When Disease Due to Gallstones",
      "subtitle": "Prognosis for pancreatitis due to gallstones"
    },
    {
      "id": "breast-cancer-recurrence-risk-after-mastectomy",
      "title": "Breast Cancer Recurrence Risk After Mastectomy",
      "subtitle": "Breast cancer recurrence risk post-mastectomy"
    },
    {
      "id": "pneumonia-risk-post-operative-period-non-cardiac-surgery",
      "title": "Pneumonia Risk in Post Operative Period of Non-Cardiac Surgery",
      "subtitle": "Estimates post-op pneumonia risk"
    },
    {
      "id": "bleeding-risk-major-complication-warfarin-therapy",
      "title": "Bleeding Risk (Major Complication) on Warfarin Therapy",
      "subtitle": "Risk of major bleeding complications for patients on warfarin"
    },
    {
      "id": "bleeding-risk-index-warfarin-therapy",
      "title": "Bleeding Risk Index for Warfarin Therapy",
      "subtitle": "Risk of bleeding based on various risk factors"
    },
    {
      "id": "myelodysplastic-syndrome-international-prognostic-scoring-system",
      "title": "Myelodysplastic Syndrome International Prognostic Scoring System",
      "subtitle": "Myelodysplastic Syndrome staging"
    },
    {
      "id": "creatinine-clearance-cockcroft-gault",
      "title": "Creatinine Clearance Cockcroft Gault",
      "subtitle": "Predicts creatinine clearance from serum creatinine"
    },
    {
      "id": "oxygen-content-venous-blood",
      "title": "Oxygen Content of Venous Blood",
      "subtitle": "Calculates venous blood oxygen content"
    },
    {
      "id": "dose-adjustment-body-surface-area",
      "title": "Dose Adjustment for Body Surface Area",
      "subtitle": "Adjusted dose based on BSA"
    },
    {
      "id": "oxygen-content-arterial-blood",
      "title": "Oxygen Content of Arterial Blood",
      "subtitle": "Calculates arterial blood oxygen content"
    },
    {
      "id": "estimated-blood-volume",
      "title": "Estimated Blood Volume",
      "subtitle": "Estimated Blood volume for different patient groups"
    },
    {
      "id": "sodium-correction-hyperglycemia",
      "title": "Sodium Correction in Hyperglycemia",
      "subtitle": "Calculates sodium in hyperglycemia"
    }
  ],
  "calculators": [
    {
      "id": "chads2-score-for-atrial-fibrillation-stroke-risk",
      "title": "CHADS₂ Score for Atrial Fibrillation Stroke Risk",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Congestive Heart Failure, past or current",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Hypertension treated or untreated",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Age ≥ 75 years",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Diabetes Mellitus",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Prior ischemic stroke, TIA or thromboembolism",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/2"
          }
        }
      ],
      "results": {
        "0": [
          "Low risk of thromboembolic event. 1.9% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "1": [
          "Intermediate risk of thromboembolic event. 2.8% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "2": [
          "Intermediate risk of thromboembolic event. 4.0% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "3": [
          "High risk of thromboembolic event. 5.9% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "4": [
          "High risk of thromboembolic event. 8.5% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "5": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no warfarin.)",
          "By points directly: High risk of thromboembolic event. 12.5% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ],
        "6": [
          "Note: While history of stroke provides 2 points, most physicians would move these patients directly to the high risk group (>8.5% risk of event per year if no warfarin.)",
          "By points directly: High risk of thromboembolic event. 18.2% risk of event per year if no warfarin.",
          "The adjusted stroke rate was the expected stroke rate per 100 person-years derived from the multivariable model assuming that aspirin was not taken."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates stroke risk in patients with atrial fibrillation",
          "The CHADS₂ score is one of several risk stratification schemes that can help determine the 1 year risk of an ischemic stroke in a non-anticoagulated patient with non-valvular atrial fibrillation and determine which antithrombotic therapy is most appropriate",
          "The CHA₂-DS₂-VASC score may be a better tool to assess stroke risk in patients with atrial fibrillation.  It risk stratifies these patients better than the CHADS2 score"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Gage BF, Waterman AD, Shannon W, et. al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.",
          "Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P.; Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004 Oct 19;110(16):2287-92",
          "Go AS, Hylek EM, Chang Y, et. al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003 Nov 26;290(20):2685-92."
        ]
      }
    },
    {
      "id": "curb-65-pneumonia-severity-score",
      "title": "CURB-65 Pneumonia Severity Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Confusion",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Urea (BUN > 19 mg/dL or 7 mmol/L)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Respiratory Rate ≥ 30 per minute",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Blood Pressure: Systolic < 90 mmHg or Diastolic ≤ 60 mmHg",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Age ≥ 65 years",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": [
          "Low risk: 0.6% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "1": [
          "Low risk: 2.7% 30-day mortality.",
          "Consider outpatient treatment."
        ],
        "2": [
          "Moderate risk: 6.8% 30-day mortality.",
          "Short inpatient hospitalization or closely supervised outpatient treatment."
        ],
        "3": [
          "Severe risk: 14.0% 30-day mortality.",
          "Severe pneumonia; hospitalize and consider potential ICU admission."
        ],
        "4": [
          "Highest risk: 27.8% 30-day mortality.",
          "Severe pneumonia; hospitalize and consider potential ICU admission."
        ],
        "5": [
          "Highest risk: 27.8% 30-day mortality.",
          "Severe pneumonia; hospitalize and consider potential ICU admission."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "CURB-65 estimates the mortality of community-acquired pneumonia to help determine inpatient vs outpatient treatment",
          "Compared to the Pneumonia Severity Index (PSI), CURB-65 offers equal sensitivity of mortality prediction due to community-acquired pneumonia.  The specificity of CURB-65 (74.6%) is also higher than PSI (52.2%)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lim WS, van der Eerden MM, Laing R, et. al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.",
          "Lim WS, Macfarlane JT, Boswell TC, et. al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001 Apr;56(4):296-301."
        ]
      }
    },
    {
      "id": "ransons-criteria-for-pancreatitis-mortality",
      "title": "Ranson's Criteria for Pancreatitis Mortality",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria at time of patient admission to hospital",
          "data": [
            {
              "type": "checkbox",
              "label": "Age > 55",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Glucose >200 mg/dL (>10 mmol/L)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "WBC > 16,000",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "AST > 250",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "LDH > 350",
              "points": "1"
            }
          ]
        },
        {
          "group": "Criteria that may develop over the first 2 hospital days",
          "data": [
            {
              "type": "checkbox",
              "label": "Hct drops 10% or greater from time of admission",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "BUN increases >5 mg/dL (>1.79 mmol/L) from time of admission",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Ca <8 mg/dL (<2 mmol/L) within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Arterial pO2 <60 mmHg within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Base deficit (24 - HCO3) >4 mg/dL within 48 hours",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Fluid needs > 6L within 48 hours",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 2": ["Mortality is 1%"],
        "3 - 4": ["Mortality is 16%"],
        "5 - 6": ["Mortality is 40%"],
        "7 - 11": ["Mortality is almost 100%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates mortality of patients with pancreatitis based on initial and 48 hour lab values",
          "The BISAP score is another alternative to estimate pancreatitis mortality with fewer variables that is as accurate"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gyne Ob. 143:209, 1976."
        ]
      }
    },
    {
      "id": "amoxicillin-pediatric-ear-nose-throat",
      "title": "Amoxicillin Pediatric - Ear, Nose, & Throat Infections",
      "type": "formula",
      "info": {
        "drugName": "Amoxicillin",
        "drugIndication": "Ear, Nose & Throat Infections | Pediatric",
        "drugDosageInformation": [
          {
            "title": "Mild to Moderate infections",
            "content": [
              "<3 months: ≤30mg/kg/day PO divided q12hr for 48-72 hours; for ≥10 days for S pyogenes infections",
              ">3 months and <40kg: 25mg/kg/day PO divided q12 hr or 20mg/kg/day divided q8hr",
              ">40kg: 500 mg PO q12hr or 250 mg PO q8hr for 10-14 days"
            ]
          },
          {
            "title": "Severe Infections",
            "content": [
              "<3 months: ≤30mg/kg/day PO divided q12hr for 48-72 hours; for ≥10 days for S pyogenes infections",
              ">3 months and <40kg: 45mg/kg/day PO divided q12 hr or 40mg/kg/day PO divided q8hr",
              ">40kg: 500 mg PO q12hr or 250 mg PO q8hr for 10-14 days"
            ]
          },
          {
            "title": "Tonsilitis/Streptococcal pharyngitis",
            "content": [
              "50mg/kg PO qDay for 10 days, not to exceed 1g/day, or 25mg/kg PO BID for 10 days, not to exceed 500mg/dose",
              ">12 years: 775 mg PO qDay for 10days, taken within 1 hour after meal (swallow tablet whole; do not crush or chew)"
            ]
          }
        ]
      },
      "questions": [
        {
          "group": "Dosage",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter drug dose",
              "values": ["mg/kg", "gm/kg", "mcg/kg"]
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter patient weight",
              "values": ["kg", "lbs"]
            }
          ]
        },
        {
          "group": "Liquid Formulation (optional)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter medication amount",
              "values": ["mg", "gm", "mcg"]
            }
          ]
        },
        {
          "group": "Per Volume",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter medication volume",
              "values": ["mL", "L"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates mortality of patients with pancreatitis based on initial and 48 hour lab values",
          "The BISAP score is another alternative to estimate pancreatitis mortality with fewer variables that is as accurate"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gyne Ob. 143:209, 1976."
        ]
      }
    },
    {
      "id": "cha2ds2-vasc-score-for-stroke-risk",
      "title": "CHA₂DS₂-VASc Score for Stroke Risk",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Clinical Features",
          "data": [
            {
              "type": "checkbox",
              "label": "Congestive Heart Failure / LV dysfunction",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Hypertension",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Diabetes Mellitus",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Stroke or TIA or thromboembolism",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label":
                "Vascular disease (History of MI, PVD or aortic atherosclerosis)",
              "points": "1"
            }
          ]
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "< 65 yrs | 65-74 yrs | ≥ 75 yrs",
            "points": "0/1/2"
          }
        },
        {
          "group": "Sex",
          "data": {
            "type": "radio",
            "options": "Male | Female",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0": [
          "Low risk of stroke. Patient may not require anticoagulation.",
          "Stroke risk was 0.2% per year in 90K patients and 0.3% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "1": [
          "Low to moderate risk of stroke. Consider antiplatelet or anticoagulation therapy",
          "Stroke risk was 0.6% per year in 90K patients and 0.9% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "2": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 2.2% per year in 90K patients and 2.9% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "3": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 3.2% per year in 90K patients and 4.6% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "4": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 4.8% per year in 90K patients and 6.7% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "5": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 7.2% per year in 90K patients and 10.0% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "6": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 9.7% per year in 90K patients and 13.6% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "7": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 10.8% per year in 90K patients and 15.2% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "8": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 11.2% per year in 90K patients and 15.7% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ],
        "9": [
          "Moderate-high risk of stroke. Patient should be an anticoagulation candidate",
          "Stroke risk was 12.2% per year in 90K patients and 17.4% risk of stroke/TIA/systemic embolism (the Swedish Atrial Fibrillation Cohort Study)"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The CHA₂DS₂-VASc score was developed after identifying additional stroke risk factors in patients with Atrial Fibrillation",
          "The Lip-Halperin Chest publication seeks to refine the the CHADS₂ risk stratification score by adding more points for patients ≥75 yrs and for vascular disease.",
          "A 0 score is a low risk and may not require anticoagulation therapy, a 1 score is of low to moderate risk and one may consider antiplatelet or anticoagulation and a score of 2 or more is moderate high risk and patients should be put on anticoagulation therapy"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 Jun;123(6):484-8. Review.",
          "Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72."
        ]
      }
    },
    {
      "id": "glasgow-coma-scale",
      "title": "Glasgow Coma Scale",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Eye opening",
          "data": {
            "type": "radio",
            "options": "Spontaneous | To sound | To pressure | No eye opening",
            "points": "4/3/2/1"
          }
        },
        {
          "group": "Best motor response",
          "data": {
            "type": "radio",
            "options":
              "Obeys verbal commands | Localizes pain | Normal flexion from pain | Abnormal flexion from pain | Extension to pain | No motor response",
            "points": "6/5/4/3/2/1"
          }
        },
        {
          "group": "Best Verbal Response",
          "data": {
            "type": "radio",
            "options":
              "Oriented | Confused | Inappropriate words | Only moans or groans | No verbal response",
            "points": "5/4/3/4/2/1"
          }
        }
      ],
      "results": {
        "3 - 14": ["Abnormal"],
        "15": ["Normal"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Glasgow Coma Scale (GCS) estimates the coma severity based on Eye, Verbal and Motor criteria.",
          "The GCS can be indicative of how critically ill a patient is. Trauma patients presenting with a GCS < 15 points require close attention and re-assessment",
          "The GCS is the standard used in the pre-hospital and acute care setting to evaluate for mental status assessment in both traumatic and non-traumatic presentations."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Teasdale G, Jennett B. Assessment of coma and impaired conciousness: a practical scale. Lancet. 1974; Jul 13;2:81-84.",
          "Teasdale G, Knill-Jones R, van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry 1978;41:603-10.",
          "The Glasgow Structured Approach to Assessment of the Glasgow Coma Scale www.glasgowcomascale.org"
        ]
      }
    },
    {
      "id": "apgar-score",
      "title": "Apgar Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Pulse heart rate",
          "data": {
            "type": "radio",
            "options": "≥100 bpm | <100 bpm/Absent",
            "points": "2/1/0"
          }
        },
        {
          "group": "Respiration/Lung maturity",
          "data": {
            "type": "radio",
            "options": "Good or crying | Slow or irregular | None",
            "points": "2/1/0"
          }
        },
        {
          "group": "Muscle tone",
          "data": {
            "type": "radio",
            "options": "Active motion | Some extremity flexion | Limp",
            "points": "2/1/0"
          }
        },
        {
          "group": "Skin appearance/Color",
          "data": {
            "type": "radio",
            "options":
              "All Pink | Bluish extremities, pink body | Blue or pale",
            "points": "2/1/0"
          }
        },
        {
          "group": "Reflex irritability/Grimace",
          "data": {
            "type": "radio",
            "options": "Sneeze and cough or crying | Grimacing | Silence",
            "points": "2/1/0"
          }
        }
      ],
      "results": {
        "0 - 3": ["Distress, needs intervention"],
        "4 - 6": ["Fairly low"],
        "7 - 10": ["Normal"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Apgar is a quick test performed on neonates at 1 and 5 minutes after birth.",
          "The 1 minute score determines how well the baby tolerated the birthing process. The 5 minute score tells how well the baby is doing outside the mother's womb.",
          "Per Neonatal Resuscitation Program, scoring continues at 5 min intervals until reaching a score of 7 or until 20 minutes of life is encountered.  Scored by any provider with direct patient contact at the specified time.",
          "Testing for Reflex irritability involves a rapid, tangential slap of the sole of the baby's foot "
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Apgar V. A proposal of a New Method of Evaluation of the Newborn Infant. Current Researches in Anesthesia and Analgesia. 1953, 32: 261-267.",
          "Apgar V, Holaday DA, James LS, et. al. Evaluation of the newborn infant. JAMA. 1958, 168: 1985-1988.",
          "Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001 Feb 15;344(7):467-71."
        ]
      }
    },
    {
      "id": "metabolic-syndrome-criteria-aha-nhlbi-2005",
      "title": "Metabolic Syndrome Criteria (AHA/NHLBI 2005)",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label":
                "Abdominal obesity (Male waist > 101 cm (40 in). Female waist > 88.9cm (35 in)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Triglycerides ≥ 150 mg/dL or on Triglyceride lowering Rx",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "HDL cholesterol (Male < 40; Female < 50) or on HDL improvement Rx",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Blood Pressure ≥130/≥85 or on BP Rx",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Fasting glucose ≥100 mg/dL or on Glucose lowering Rx",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 2": ["Absent"],
        "3 - 5": ["Present"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "This criteria set was proposed by the American Heart Association and the National Heart Lung and Blood Institute.",
          "Metabolic syndrome is a constellation of interrelated risk factors of metabolic origin that appear to directly promote the development of atherosclerotic cardiovascular disease.",
          "The predominant underlying risk factors for the syndrome appear to be abdominal obesity and insulin resistance; other associated conditions can be physical inactivity, aging and hormonal imbalance."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Grundy SM, Cleeman JI, Daniels SR, et. al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52. Epub 2005 Sep 12."
        ]
      }
    },
    {
      "id": "dvt-probability-wells-score-system",
      "title": "DVT Probability: Wells Score System",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Clinical Findings",
          "data": [
            {
              "type": "checkbox",
              "label":
                "Paralysis, paresis or recent orthopedic casting of lower extremity",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Recently bedridden (> 3 days) or major surgery within last 4 weeks",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Localized tenderness in deep vein system",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Entire leg is swollen",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Calf swelling >3 cm compared to other leg (measured 10 cm below tibial tuberosity)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Pitting edema, confined to symptomatic leg",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Collateral non varicose superficial veins",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Active cancer, treatment or palliation within 6 months",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Alternative diagnosis more likely than DVT (Baker's cyst, cellulitis, muscle damage, superficial venous thrombosis, post phlebitic syndrome, inguinal lymphadenopathy, external venous compression)",
              "points": "-2"
            }
          ]
        }
      ],
      "results": {
        "-2 - 0": ["Low risk; 5% probability of DVT"],
        "1 - 2": ["Moderate risk of DVT; 17% probability of DVT"],
        "3 - 8": ["High risk of DVT; 53% probability of DVT"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The Wells clinical prediction guide quantifies the probability of deep venous thrombosis (DVT) in patients",
          "The model enables the reliable stratification of patients into high, moderate and low risk categories.",
          "Based on the 2003 Wells study, DVT can be ruled out in a patient who is judged clinically unlikely to have a DVT and who has a negative D-dimer test. Ultrasound testing can be safely omitted in such patients. "
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Wells PS, Anderson DR, Bormanis J, et. al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997 Dec 20-27;350(9094):1795-8.",
          "Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003 Sep 25;349(13):1227-35."
        ]
      }
    },
    {
      "id": "tia-prognosis-risk-of-stroke-by-90-days-after-presentation",
      "title": "TIA Prognosis: Risk of Stroke by 90 Days After Presentation",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Patient > 60 yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Concurrent Diabetes",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "TIA lasted > 10 minutes",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient experienced weakness during TIA",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient experienced speech problems during TIA",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": ["90 Day Risk of Stroke: Virtually no Risk"],
        "1": ["90 Day Risk of Stroke: 3% Risk"],
        "2": ["90 Day Risk of Stroke: 7% Risk"],
        "3": ["90 Day Risk of Stroke: 11% Risk"],
        "4": ["90 Day Risk of Stroke: 15% Risk"],
        "5": ["90 Day Risk of Stroke: 34% Risk"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000; 284: 2901-6."
        ]
      }
    },
    {
      "id": "timi-risk-score-for-stemi",
      "title": "TIMI Risk Score for STEMI",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Diabetes, Hypertension or Angina",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Systolic Blood Pressure <100 mm Hg",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "Heart rate > 100 bpm",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "Killip class II-IV",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "Body weight < 67 kg (150 lb)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Anterior ST elevation or Left Bundle Branch Block",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Time to treatment > 4 hrs",
              "points": "1"
            }
          ]
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "≥ 75 yrs | 65-74 yrs | < 65 yrs",
            "points": "3/2/0"
          }
        }
      ],
      "results": {
        "0": ["30 Day mortality after an MI 0.8%"],
        "1": ["30 Day mortality after an MI 1.6%"],
        "2": ["30 Day mortality after an MI 2.2%"],
        "3": ["30 Day mortality after an MI 4.4%"],
        "4": ["30 Day mortality after an MI 7.3%"],
        "5": ["30 Day mortality after an MI 12%"],
        "6": ["30 Day mortality after an MI 16%"],
        "7": ["30 Day mortality after an MI 23%"],
        "8": ["30 Day mortality after an MI 27%"],
        "9 - 14": ["30 Day mortality after an MI 36%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "TIMI Risk Score predicts 30 day mortality in patients with ST Elevation Acute Myocardial Infarction (STEMI).",
          "The TIMI Score for STEMI was developed from the InTIME II trial of 15K STEMI patients which included studying these patients for thrombolytics. It did not include patients with cardiogenic shock or severe hypertension (BP >180/>110)",
          "Entry criteria: Chest pain for > 30 minutes, ST elevation, symptom onset < 6 hours, fibrinolytic eligible.",
          "Can be used on patients who are post-cath who may have bleeding risks to objectify risk-benefit of post PCI medications."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Morrow DA, Antman EM, Charlesworth A, et. al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000 Oct 24; 102(17):2031-7.",
          "Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP, Giugliano RP, McCabe CH, Barron HV, Braunwald E. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19;286(11):1356-9."
        ]
      }
    },
    {
      "id": "timi-risk-score-for-unstable-angina-nstemi",
      "title": "TIMI Risk Score for Unstable Angina/NSTEMI",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Age ≥ 65",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "≥ 3 CAD risk factors (Hypertension, Diabetes, High Cholesterol, Family History of CAD, Current Smoker)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Known CAD with > 50% stenosis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Aspirin use in the past 7 days",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Severe angina ≥ 2 episodes in 24 hrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Elevated cardiac markers",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "ST deviation ≥ 0.5 mm",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": [
          "5% risk at 2 weeks of: Death new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ],
        "2": [
          "8% risk at 2 weeks of: Death new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ],
        "3": [
          "13% risk at 2 weeks of: Death new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ],
        "4": [
          "20% risk at 2 weeks of: Death new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ],
        "5": [
          "26% risk at 2 weeks of: Death, new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ],
        "6 - 7": [
          "41% risk at 2 weeks of: Death, new or recurrent MI, severe recurrent ischemia requiring urgent revascularization"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Estimates mortality in patients with unstable angina and non-ST elevation myocardial infarction (MI)",
          "Entry criteria: UA or NSTEMI defined as ischemic pain at rest within the past 24 hours with evidence of Coronary Artery Disease (ST segment deviation or + markers)",
          "TIMI Risk Score for Unstable Angina/NSTEMI can be used to help risk stratify patients with anginal symptoms but is better suited for patients with confirmed NSTEMI or unstable angina",
          "TIMI Risk Score for Unstable Angina/NSTEMI is the best known chest pain risk score tool, however newer tools such as the GRACE score provide better risk stratification for low vs. non-low risk patients."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Antman EM1, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16;284(7):835-42."
        ]
      }
    },
    {
      "id": "nih-stroke-score",
      "title": "NIH Stroke Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "1A: Level of Consciousness",
          "data": {
            "type": "radio",
            "options":
              "Alert | Not alert, but arousable by minor stimulation | Not alert, requires repeated stimulation to attend | Coma",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "1B: Ask Patient the Month and His/Her Age",
          "data": {
            "type": "radio",
            "options":
              "Answers both questions correctly | Answers one question correctly | Neither correct",
            "points": "0/1/2"
          }
        },
        {
          "group":
            "1C: Open and Close Eyes on Command/Grip and release non-paretic hand ",
          "data": {
            "type": "radio",
            "options":
              "Obeys both correctly | Obeys one correctly | Both incorrect",
            "points": "0/1/2"
          }
        },
        {
          "group": "2: Best Gaze (only horizontal eye movement)",
          "data": {
            "type": "radio",
            "options": "Normal | Partial gaze palsy | Forced deviation",
            "points": "0/1/2"
          }
        },
        {
          "group": "3: Visual Field testing",
          "data": {
            "type": "radio",
            "options":
              "No visual field loss | Partial hemianopia | Complete hemianopia | Bilateral hemianopia or Patient is bilaterally blind",
            "points": "0/1/2/3"
          }
        },
        {
          "group":
            "4: Facial Palsy (Ask patient to show teeth or raise eyebrows and close eye)",
          "data": {
            "type": "radio",
            "options":
              "Normal symmetrical movement | Minor paralysis | Partial paralysis (total or near total paralysis of lower face) | Complete paralysis of one or both sides",
            "points": "0/1/2/3"
          }
        },
        {
          "group":
            "5A: Motor Function of Right Arm (Count out loud and use your fingers to show patient your count)",
          "data": {
            "type": "radio",
            "options":
              "No drift for 10 sec | Drift limb holds 90 (or 45 deg) but drifts down before full 10 sec | Some effort against gravity | No effort against gravity | No movement | Amputation or joint fusion",
            "points": "0/1/2/3/4/0"
          }
        },
        {
          "group":
            "5B: Motor Function of Left Arm (Count out loud and use your fingers to show patient your count)",
          "data": {
            "type": "radio",
            "options":
              "No drift for 10 sec | Drift limb holds 90 (or 45 deg) but drifts down before full 10 sec | Some effort against gravity | No effort against gravity | No movement | Amputation or joint fusion",
            "points": "0/1/2/3/4/0"
          }
        },
        {
          "group":
            "6A: Motor Function of Right Leg (Hold the leg at 30 deg, always tested in supine position)",
          "data": {
            "type": "radio",
            "options":
              "No drift for 5 sec | Drift, leg falls by end of 5 sec | Some effort against gravity | No effort against gravity, leg falls to bed immediately | No movement | Amputation or joint fusion",
            "points": "0/1/2/3/4/0"
          }
        },
        {
          "group":
            "6B: Motor Function of Left Leg (Hold the leg at 30 deg, always tested in supine position)",
          "data": {
            "type": "radio",
            "options":
              "No drift for 5 sec | Drift, leg falls by end of 5 sec | Some effort against gravity | No effort against gravity, leg falls to bed immediately | No movement | Amputation or joint fusion",
            "points": "0/1/2/3/4/0"
          }
        },
        {
          "group": "7: Limb Ataxia (Test with eyes open)",
          "data": {
            "type": "radio",
            "options":
              "None | Present in 1 limb | Present in 2 limbs | Amputation or joint fusion",
            "points": "0/1/2/0"
          }
        },
        {
          "group": "8: Sensory by Pinprick",
          "data": {
            "type": "radio",
            "options":
              "Normal | Mild to moderate sensory loss | Severe or total sensory loss",
            "points": "0/1/2"
          }
        },
        {
          "group":
            "9: Best Language (Describe a picture, name items, read sentences)",
          "data": {
            "type": "radio",
            "options":
              "No aphasia | Mild - Moderate aphasia | Severe aphasia | Mute",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "10: Dysarthria (read or repeat words)",
          "data": {
            "type": "radio",
            "options":
              "Normal | Mild to Moderate slurring | Severe dysarthria | Intubated or other physical impediment to testing",
            "points": "0/1/2/0"
          }
        },
        {
          "group": "11: Extinction and Inattention (Neglect)",
          "data": {
            "type": "radio",
            "options":
              "No abnormality | Visual, tactile, auditory, spatial or personal inattention or extinction to bilateral simultaneous stimulation in one of the sensory modalities | Severe hemi-inattention or extinction to more than one modality",
            "points": "0/1/2"
          }
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "The NIH Stroke Score is used to quantify patient stroke severity and to track outcomes, improvement or deteoriation of a stroke",
          "If the patient has a prior known neurological deficit (e.g. Blindness, Quadriplegia, Language barriers etc.), it becomes even more complicated to evaluate. Refer to the NIH Stroke Scale Website for more details.",
          "Scores > 22 are considered very significant and may predict increased complication risk.",
          "If the patient's arm or leg cannot be tested due to amputation or other limitation such as joint fusion, untestable is recorded and no points are counted."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Brott T, Adams HP Jr, Olinger CP, et. al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989 Jul;20(7):864-70.",
          "NIH Stroke Scale https://stroke.nih.gov/resources/scale.htm"
        ]
      }
    },
    {
      "id": "bleeding-risk-on-warfarin-therapy-any-bleeding-complication",
      "title": "Bleeding Risk on Warfarin Therapy (Any Bleeding Complication)",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Age >= 60",
              "points": "1.6"
            },
            {
              "type": "checkbox",
              "label": "Malignacy Present",
              "points": "2.2"
            }
          ]
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "Female | Male",
            "points": "1.3/0"
          }
        }
      ],
      "results": {
        "0": ["Risk of any bleeding complications: 0-4%"],
        "1.3 - 3": ["Risk of any bleeding complications: 6-8%"],
        "3.1 - 5.1": ["Risk of any bleeding complications: 17-26%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999; 159: 457-60."
        ]
      }
    },
    {
      "id": "abcd2-score-for-tia",
      "title": "ABCD² Score for TIA",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Age ≥ 60 yrs",
          "data": {
            "type": "radio",
            "options": "Yes | No",
            "points": "1/0"
          }
        },
        {
          "group": "Blood Pressure ≥ 140/90 mmHg",
          "data": {
            "type": "radio",
            "options": "Yes | No",
            "points": "1/0"
          }
        },
        {
          "group": "Clinical features of TIA",
          "data": {
            "type": "radio",
            "options":
              "Unilateral weakness | Speech disturbance without weakness | Other symptoms",
            "points": "2/1/0"
          }
        },
        {
          "group": "Duration of symptoms",
          "data": {
            "type": "radio",
            "options": "≥60 min | 10-59 min | <10 min",
            "points": "2/1/0"
          }
        },
        {
          "group": "Diabetes history",
          "data": {
            "type": "radio",
            "options": "Yes | No",
            "points": "1/0"
          }
        }
      ],
      "results": {
        "0 - 3": [
          "Low Risk; 2-day stroke risk 1.0%, 7-day stroke risk 1.2%, 90-day stroke risk 3.1%"
        ],
        "4 - 5": [
          "Moderate Risk; 2-day stroke risk 4.1%, 7-day stroke risk 5.9%, 90-day stroke risk 9.8%"
        ],
        "6 - 7": [
          "High Risk; 2-day stroke risk 8.1%, 7-day stroke risk 11.7%, 90-day stroke risk 17.8%"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The ABCD² score was developed to help stratify the stroke risk for patients presenting with a transient ischmeic attack (TIA).",
          "The score was developed in a non-emergency/outpatient setting. It has been shown to have lower accuracy when used by non-specialists.",
          "The largest prospective study using the ABCD² score in the emergency department showed that the score performed poorly (low sensitivity for low risk patients and low specificity for high risk patients)",
          "Several other studies have shown that as the ABCD² score increases the risk of a subsequent stroke increases",
          "Patients who have a low baseline risk of stroke (<2.0%) are at a low risk for having a stroke in the next 7 days (0.4-0.8%)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Johnston SC1, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007 Jan 27;369(9558):283-92."
        ]
      }
    },
    {
      "id": "has-bled-score-for-major-bleeding-risk",
      "title": "HAS-BLED Score for Major Bleeding Risk",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Uncontrolled hypertension (Systolic ≥ 160mmHg)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Renal disease (Dialysis, transplant or Creatinine >2.26mg/dL (200µmol/L)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Liver disease (Cirrhosis or bilirubin levels >2x normal with AST/ALT/AP >3x normal)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Stroke history",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Prior major bleeding or predisposition to bleeding",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Labile INR (Unstable/High INRs, time in therapeutic range <60%)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Alcohol use ≥ 8 drinks/week",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Age > 65 yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Medication usage that predisposes patient to bleeding (NSAIDs, Antiplatelet agents)",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": [
          "Low Risk for major bleeding (~1 in 100 patient years); Anticoagulation should be considered"
        ],
        "2": [
          "Moderate Risk for major bleeding (~2 in 100 patient years); Anticoagulation can be considered"
        ],
        "3 - 10": [
          "High Risk for major bleeding; Alternatives to anticoagulation should be considered"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "HAS-BLED Score estimates the risk of major bleeding for atrial fibrillation patients to determine whether to start anticoagulation therapy",
          "Scores >5 were too rare to determine risk but the risk of major bleeding is likely >10%",
          "A study comparing HAS-BLED to HEMORR2HAGES and ATRIA showed the HAS-BLED score was superior in assessing risk"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. Epub 2010 Mar 18.",
          "Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024. Epub 2010 Nov 24."
        ]
      }
    },
    {
      "id": "cardiac-risk-index-aaa-surgery",
      "title": "Cardiac Risk Index for AAA Surgery",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label":
                "Patient has Coronary artery disease (MI or positive stress test)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Congestive Heart Failure",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Cerebrovascular disease (TIA or stroke)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient has diabetes and is on insulin",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Chronic renal insufficiency (Creatinine > 2mg/dL or 176.8 µmol/L)",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": ["Approximate risk of cardiac complication: up to 7%"],
        "2": ["Approximate risk of cardiac complication: 3.8%"],
        "3 - 5": ["Approximate risk of cardiac complication: 11.5%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The index score helps to identify patients at higher risk for cardiac complications post surgery",
          "In the Lee study, patients with 2 risk factors had a paradoxical decrease in cardiac complication rates"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100: 1043-9."
        ]
      }
    },
    {
      "id": "cardiac-risk-index-abdominal-surgery",
      "title": "Cardiac Risk Index for Abdominal Surgery",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label":
                "Patient has Coronary artery disease (MI or positive stress test)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Congestive Heart Failure",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Cerebrovascular disease (TIA or stroke)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient has diabetes and is on insulin",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Chronic renal insufficiency (Creatinine > 2mg/dL or 176.8 µmol/L)",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": ["Approximate risk of cardiac complication: <1%"],
        "2": ["Approximate risk of cardiac complication: 3%"],
        "3 - 5": ["Approximate risk of cardiac complication: 8.1%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100: 1043-9."
        ]
      }
    },
    {
      "id": "cardiac-risk-index-non-aaa-vascular-surgery",
      "title": "Cardiac Risk Index for Non-AAA Vascular Surgery",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Planned surgery type is high risk",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Coronary Artery disease",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Congestive Heart Failure",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of Cerebrovascular disease(TIA or stroke)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient has diabetes and is on insulin",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Chronic renal insufficiency (Creatinine > 2mg/dL or 176.8 µmol/L)",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": ["Approximate risk of cardiac complication: <1%"],
        "2": ["Approximate risk of cardiac complication: 8%"],
        "3 - 6": ["Approximate risk of cardiac complication: 12.5%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100: 1043-9."
        ]
      }
    },
    {
      "id": "jones-criteria-for-diagnosis-of-rheumatic-fever",
      "title": "Jones Criteria for Diagnosis of Rheumatic Fever",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Evidence of antecedent Strep infection: ASO / Strep antibodies / Strep group A throat culture / Recent scarlet fever / anti-deoxyribonuclease B / anti-hyaluronidase",
              "points": "1"
            }
          ]
        },
        {
          "group": "Major Diagnostic Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Carditis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Polyarthritis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Chorea",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Erythema marginatum",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Subcutaneous Nodules",
              "points": "1"
            }
          ]
        },
        {
          "group": "Minor Diagnostic Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Fever",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Arthralgia",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Previous rheumatic fever or rheumatic heart disease",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Acute phase reactions: ESR / CRP / Leukocytosis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Prolonged PR interval",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Diagnostic: 1 Required Criteria and 2 Major Criteria and 0 Minor Criteria",
          "Diagnostic: 1 Required Criteria and 1 Major Criteria and 2 Minor Criteria"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. JAMA. 1992 Oct 21;268(15):2069-73. Erratum in: JAMA 1993 Jan 27;269(4):476."
        ]
      }
    },
    {
      "id": "endocarditis-diagnostic-criteria-duke-criteria",
      "title": "Endocarditis Diagnostic Criteria - Duke Criteria",
      "type": "formula",
      "questions": [
        {
          "group": "Major Diagnostic Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Positive blood culture for typical Infective Endocarditis organisms (strep viridins or bovis, HACEK, staph aureous without other primary site, enterococcus), from 2 separate blood cultures or 2 positive cultures from samples drawn > 12 hours apart, or 3 or a majority of 4 separate cultures of blood (first and last sample drawn 1 hour apart)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Echocardiogram with oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation, or abscess, or new partial dehiscence of prosthetic valve or new valvular regurgitation",
              "points": "1"
            }
          ]
        },
        {
          "group": "Minor Diagnostic Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Predisposing heart condition or intravenous drug use",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Temp > 38.0° C (100.4° F)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Vascular phenomena: arterial emboli, pulmonary infarcts, mycotic aneurysms, intracranial bleed, conjunctival hemorrhages, Janeway lesions",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Microbiological evidence: positive blood culture but does not meet a major criterion as noted above or serological evidence of active infection with organism consistent with endocarditis (excluding coag neg staph, and other common contaminants)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Echocardiographic findings: consistent with endocarditis but do not meet a major criterion as noted above",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Diagnostic : 2 Major Criteria and 0 Minor Criteria",
          "Diagnostic : 1 Major Criteria and 3 Minor Criteria",
          "Diagnostic : 0 Major Criteria and 5 Minor Criteria"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. American Journal of Medicine. 96(3):200-9, 1994.",
          "Lukes AS, Bright DK, Durack DT. Diagnosis of infective endocarditis. Infect Dis Clin North Am. 1993 Mar;7(1):1-8. Review."
        ]
      }
    },
    {
      "id": "ottawa-ankle-rule-for-the-use-of-x-ray-in-ankle-injury",
      "title": "Ottawa Ankle Rule for the Use of X-Ray in Ankle Injury",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Pain near the malleous",
              "points": "1"
            }
          ]
        },
        {
          "group": "Major Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Inability to bear wieght right after the injury as well as in the emergency department (4 steps)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Bone tenderness at the posterior edge or tip of either malleolus",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "X-Ray Indicated : 1 Required Criteria and 1 Major Criteria"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Stiell IG, McKnight RD, Greenberg GH, et. al. Implementation of the Ottawa ankle rules. JAMA. 1994 Mar 16;271(11):827-832.",
          "Stiell IG, Greenberg GH, McKnight RD, et.al. Decision rules for the use of radiography in acute ankle injuries. Refinement and prospective validation. . JAMA. 1993 Mar 3;269(9):1127-32.",
          "Stiell IG, Greenberg GH, McKnight RD, et. al. A study to develop clinical decision rules for the use of radiography in acute ankle injuries. Ann Emerg Med. 1992 Apr;21(4):384-90.",
          "Stiell IG, McKnight RD, Greenberg GH, et. al. Interobserver agreement in the examination of acute ankle injury patients. Am J Emerg Med. 1992 Jan;10(1):14-17."
        ]
      }
    },
    {
      "id": "creatinine-clearance-measured",
      "title": "Creatinine Clearance (measured)",
      "type": "formula",
      "questions": [
        {
          "group": "Urine Creat",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Urine Creat",
              "values": ["mg/dL", "mcmol/L", "mg%"]
            }
          ]
        },
        {
          "group": "Serum Creat",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Serum Creat",
              "values": ["mg/dL", "mcmol/L", "mg%"]
            }
          ]
        },
        {
          "group": "Days Urine Volume",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Days Urine Volume",
              "values": ["mL", "L", "fL"]
            }
          ]
        }
      ],
      "results": {},
      "formula": {
        "type": "paragraph",
        "content": [
          "CreatClear = UrineCreatinine* DaysUrineVolume/ SerumCreatinine/1440"
        ]
      }
    },
    {
      "id": "body-mass-index-quetelet-index",
      "title": "Body Mass Index",
      "type": "formula",
      "questions": [
        {
          "group": "Height",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Height",
              "values": ["m", "in", "cm"]
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Weight",
              "values": ["kg", "lb"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "The default unit of measure for weight is kilograms and height is meters."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 00-4084.",
          "Khosla T, Lowe CR. Indices of obesity derived from body weight and height. Br J Prev Soc Med. 1967; 21: 122-128."
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": ["BMI = Weight / (Height * Height)"]
      }
    },
    {
      "id": "anion-gap",
      "title": "Anion Gap",
      "type": "formula",
      "questions": [
        {
          "group": "Na",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Norm: 136-145 mmol/L",
              "values": ["mmol/L", "mEq/L"]
            }
          ]
        },
        {
          "group": "Cl",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Norm: 98-106 mmol/L",
              "values": ["mmol/L", "mEq/L"]
            }
          ]
        },
        {
          "group": "HCO3",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Norm: 23-28 mmol/L",
              "values": ["mmol/L", "mEq/L"]
            }
          ]
        },
        {
          "group": "Albumin (Optional)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Norm: 35-55 g/L",
              "values": ["g/L", "g/dL"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "The Anion Gap calculator evaluates states of metabolic acidosis",
          "An elevated anion gap suggests the presence of a metabolic acidosis"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Figge J, et al. Anion gap and hypoalbuminemia. Crit Care Med. 1998 Nov;26(11):1807-10.",
          "Oh M.S., Carroll H.J.; The anion gap. NEJM 1977 Oct;13; 297(15):814-7."
        ]
      },
      "formula": {
        "type": "unordered-list",
        "content": [
          "Anion Gap = Na - (Cl +HCO3)",
          "Corrected Anion Gap = Anion Gap + (2.5 * (4 - Albumin))",
          "Normal Albumin is assumed to be 4.4 g/dL"
        ]
      }
    },
    {
      "id": "parkland-formula-for-burns",
      "title": "Parkland Formula for Burns",
      "type": "formula",
      "questions": [
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Weight",
              "values": ["kg", "lb"]
            }
          ]
        },
        {
          "group": "Percent Nonsuperficial Burn Area",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Percent Nonsuperficial Burn Area",
              "values": ["%"],
              "disabled": true
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Fluid needs calculated according to the Parkland formula provide only a guide to baseline fluid requirements in patients with major burns. Superficial burns are not included in the calculation",
          "Patients with burn shock require immediate, aggressive IV fluid resuscitation and their fluid needs can exceed those estimated by the Parkland formula",
          "The fluid needs of burn patients may vary extensively. Use physiological parameters (e.g. Blood pressure, pulse rate, urine output) to determine the adequacy of fluid resuscitation",
          "Elderly patients or children with major burns have additional fluid needs"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Saffle, JR. Practice guidelines for burn care. J Burn Care. 2001; 22(Suppl):i.",
          "Slater H, Goldfarb IW. The management of burn trauma: a house staff handbook. Western Pennsylvania Hospital. 2003: p 9-12."
        ]
      },
      "formula": {
        "type": "unordered-list",
        "content": [
          "Total Crystalloid For First 24 Hours = 4 * Weight * Percent Non-superficial Burn Area",
          "Rate First 8 Hours =  Total Crystalloid / 16",
          "Rate Next 16 Hours =  Total Crystalloid / 32"
        ]
      }
    },
    {
      "id": "maintenance-fluid-calculation-for-children",
      "title": "Maintenance Fluid Calculation for Children",
      "type": "formula",
      "questions": [
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Weight",
              "values": ["kg", "lb"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "For infants 3.5 — 10kg the daily fluid requirement is 100mL/kg",
          "For children between 11—20 kg the daily fluid requirement is 1,000 mL + 50mL/kg for every kg over 10",
          "For children between >20 kg the daily fluid requirement is 1,500 mL + 20mL/kg for every kg over 20, up to a maximum of 2,400mL daily",
          "This calculation does not apply to newborn infants (i.e. from 0 to 28 days after full term delivery)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics. Vol. 19, 1957 823-832."
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": ["Fluid Rate = Daily Volume/24"]
      }
    },
    {
      "id": "cardiac-output",
      "title": "Cardiac Output",
      "type": "formula",
      "questions": [
        {
          "group": "Oxygen Consumption (O2)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Oxygen Consumption (O2)",
              "values": ["mL/min", "L/min", "L/sec", "mL/hr", "mL/sec"]
            }
          ]
        },
        {
          "group": "Hemoglobin (Hgb)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter Hemoglobin (Hgb)",
              "values": [
                "gm/dL",
                "gm/L",
                "mcg/dL",
                "mcg/mL",
                "mg%",
                "mg/dL",
                "mg/mL",
                "ng/mL"
              ]
            }
          ]
        },
        {
          "group": "O2 Saturation",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter O2 Saturation",
              "values": ["%", "fraction", "ratio"]
            }
          ]
        },
        {
          "group": "PaO2",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter PaO2",
              "values": [
                "mmHg",
                "Pascal",
                "atm",
                "bar",
                "cmH2O",
                "cmHg",
                "ftH2O",
                "gm/sqcm",
                "inH2O",
                "inHg",
                "kPa",
                "mbar",
                "psi",
                "torr"
              ]
            }
          ]
        },
        {
          "group": "O2vSat",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter O2vSat",
              "values": ["%", "fraction", "ratio"]
            }
          ]
        },
        {
          "group": "PvO2",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Please enter PvO2",
              "values": [
                "mmHg",
                "Pascal",
                "atm",
                "bar",
                "cmH2O",
                "cmHg",
                "ftH2O",
                "gm/sqcm",
                "inH2O",
                "inHg",
                "kPa",
                "mbar",
                "psi",
                "torr"
              ]
            }
          ]
        }
      ],
      "results": {},
      "formula": {
        "type": "unordered-list",
        "content": [
          "CaO2 = (Hgb*13.4*O2Sat/100) + (PaO2*0.031)",
          "CvO2 = (Hgb*13.4*O2vSat/100) + (PvO2*0.031)",
          "CO = O2Consumption/(CaO2-CvO2)"
        ]
      }
    },
    {
      "id": "pediatric-glasgow-coma-scale",
      "title": "Pediatric Glasgow Coma Scale",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Eye Opening",
          "data": {
            "type": "radio",
            "options":
              "Open spontaneously | Open to verbal stimuli | Open to pain only | No response",
            "points": "4/3/2/1"
          }
        },
        {
          "group": "Verbal Responses",
          "data": {
            "type": "radio",
            "options":
              "Coos and babbles | Irritable cries | Cries in response to pain | Moans in response to pain | No response",
            "points": "5/4/3/2/1"
          }
        },
        {
          "group": "Motor Responses",
          "data": {
            "type": "radio",
            "options":
              "Moves spontaneously/purposefully | Withdraws to touch | Withdraws to pain | Flexor posturing to pain | Extensor posturing to pain | No response",
            "points": "6/5/4/3/2/1"
          }
        }
      ],
      "results": {
        "3 - 8": ["Severe head injury (coma)"],
        "9 - 12": ["Moderate head injury"],
        "13 - 15": ["Minor head injury"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "For use only in children 2 years and younger. For children >2 years use the adult Glasgow Coma Scale",
          "The pediatric GCS can be used to assess and track a patient's mental status and level of consciousness but should not be used alone in determining management decisions in acute care settings",
          "All patients with pGCS < 15 need appropriate monitoring",
          "For patients with pGCS < 8, consider the need for intubation or definitive airway management. Take into account the entire clinical picture"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "James HE, Neurologic evaluation and support in the child with an acute brain insult. Pediatr Ann. 1986 Jan;15(1):16-22.",
          "Borgialli DA, Mahajan P. et al. Performance of the Pediatric Glasgow Coma Scale Score in the Evaluation of Children With Blunt Head Trauma. Acad Emerg Med. 2016 Aug;23(8):878-84."
        ]
      }
    },
    {
      "id": "bode-index-copd",
      "title": "BODE Index for COPD Survival Prediction",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "FEV1 % Predicted After Bronchodialator",
          "data": {
            "type": "radio",
            "options": "≥65% | 50-64% | 36-49% | ≤35%",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "6 min Walk Distance",
          "data": {
            "type": "radio",
            "options": "≥350m | 250-349m | 150-249m | ≤149m",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "mMRC Dyspnea Scale",
          "data": {
            "type": "radio",
            "options":
              "mMRC 0: Dyspnea only with strenous exercise | mMRC 1: Dyspnea when hurrying or walking a slight hill | mMRC 2: Stops for breath when walking at own pace on level ground | mMRC 3: Must stop due to breathlessness after walking 91m (100 yds) or after a few mins | mMRC 4: Cannot leave house, breathless on dressing/undressing",
            "points": "0/0/1/2/3"
          }
        },
        {
          "group": "Body Mass Index",
          "data": {
            "type": "radio",
            "options": ">21 | ≤21",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0 - 2": ["Approximate 4 year survival: 80%"],
        "3 - 4": ["Approximate 4 year survival: 67%"],
        "5 - 6": ["Approximate 4 year survival: 57%"],
        "7 - 10": ["Approximate 4 year survival: 18%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "BODE stands for Body mass index, airflow Obsruction, Dyspnea and Exercise capacity",
          "Used to predict survival in COPD patients but is not suitable to guide therapy or management",
          "BODE index is best used to help inform discussions with patients on their prognosis and goals of care",
          "Should not be used during acute exacerbations of COPD and it does not predict clinical response to therapy",
          "Patients with a higher BODE index have a higher risk of death from respiratory causes (e.g. respiratory failure, pneumonia, or pulmonary embolism)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Celli BR, Cote CG, Marin JM, et. al. The Body-Mass Index, Airflow Obstruction, Dyspnea and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.",
          "Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988 Mar;93(3):580-6.",
          "Marin JM, Carrizo SJ, Casanova C., et. al. Prediction of risk of COPD exacerbations by the BODE index. respir Med. 2009; 103(3):373-8"
        ]
      }
    },
    {
      "id": "pulmonary-embolism-wells-score",
      "title": "Pulmonary Embolism Wells Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Clinical symptoms of DVT",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "No alternative diagnosis better explains the illness",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "Pulse > 100bpm",
              "points": "1.5"
            },
            {
              "type": "checkbox",
              "label": "Immobilization for ≥3 days or surgery in last 4 weeks",
              "points": "1.5"
            },
            {
              "type": "checkbox",
              "label": "Prior history of DVT or Pulmonary Embolism",
              "points": "1.5"
            },
            {
              "type": "checkbox",
              "label": "Hemoptysis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Malignancy with treatment within 6 months",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1.5": [
          "Risk: Low probability of Pulmonary Embolism (1.3% chance in an ED patient population). Consider d-dimer testing to rule out PE"
        ],
        "2 - 6": [
          "Risk: Moderate probability of Pulmonary Embolism (16.2% chance in an ED patient population). Consider high sensitivity d-dimer testing"
        ],
        "6.5 - 13": [
          "Risk: High probability of Pulmonary Embolism (40.6% chance in an ED patient population). Consider CTA. D-dimer testing not recommended."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The Wells Score helps to stratify the risk of pulmonary embolism and is often used in conjunction with d-dimer testing to evaluate for PE",
          "It is not intended to diagnose pulmonary embolisms but to help guide clinical workup by predicting pre-test probability of PE and appropriate testing to rule out the diagnosis"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Wells PS, Anderson DR, Rodger M, et. al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000 Mar;83(3):416-20."
        ]
      }
    },
    {
      "id": "heart-score-major-cardiac-events",
      "title": "HEART Score for Major Cardiac Events",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "History",
          "data": {
            "type": "radio",
            "options":
              "Slightly suspicious | Moderately suspicious | Highly suspicious",
            "points": "0/1/2"
          }
        },
        {
          "group": "ECG/EKG",
          "data": {
            "type": "radio",
            "options":
              "Normal | Non-specific repolarization disturbance | Significant ST depression",
            "points": "0/1/2"
          }
        },
        {
          "group": "Patient Age",
          "data": {
            "type": "radio",
            "options": "<45 | 45-65 | ≥65",
            "points": "0/1/2"
          }
        },
        {
          "group":
            "Risk factors (e.g. Hypertension, High cholesterol, Diabetes, Obesity, Smoking etc.)",
          "data": {
            "type": "radio",
            "options":
              "No known risk factors | 1-2 risk factors | ≥3 risk factors or history of atherosclerotic disease",
            "points": "0/1/2"
          }
        },
        {
          "group":
            "Initial Troponin (Use local assays and corresponding cutoffs)",
          "data": {
            "type": "radio",
            "options": "≤ Normal limit | 1-2X Normal limit | >2X Normal limit",
            "points": "0/1/2"
          }
        }
      ],
      "results": {
        "0 - 3": [
          "Low Risk: 0.9-1.7% risk of adverse cardiac event. In the HEART Score study, these patients were discharged (0.99% in the retrospective study, 1.7% in the prospective study)"
        ],
        "4 - 6": [
          "Moderate Risk: 12-16.6% risk of adverse cardiac event. In the HEART Score study, these patients were admitted to the hospital. (11.6% retrospective, 16.6% prospective)"
        ],
        "7 - 10": [
          "High risk: 50-65% risk of adverse cardiac event. In the HEART Score study, these patients were candidates for early invasive measures. (65.2% retrospective, 50.1% prospective)"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The HEART score was developed in 2008 in a cohort of 122 patients presenting with chest pain in an emergency room",
          "Use in patients ≥ 21 years old presenting with symptoms suggestive of Acute Coronary Syndrome",
          "Do not use on clinically unstable patients or if new ST-segment elevation requires immediate intervention (i.e.≥ 1mm)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Six, AJ., Backus, BE., Kelder, JC., Chest pain in the emergency room: value of the HEART Score. Neth Neart J. 2008 June; 16(6):191-196"
        ]
      }
    },
    {
      "id": "quick-sofa-score-sepsis",
      "title": "qSOFA Score for Sepsis",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Altered mental status GCS <15",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Respiratory rate ≥ 22",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Systolic BP ≤ 100mmHg",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": [
          "Not High Risk; If sepsis is still suspected, continue to monitor, evaluate and initiate treatment as appropriate"
        ],
        "2 - 3": [
          "High Risk: Patients meeting this qSOFA criteria should have infection considered even if it was previously not suspected. Assess for evidence of organ dysfunction with blood test including serum lactate. Calculate full SOFA Score"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "qSOFA helps to identify high risk patients for inpatient mortality with suspected infection outside the ICU",
          "This calculator is used to predict mortality and not to diagnose sepsis, per 2017 Surviving Sepsis Guidelines",
          "A positive qSOFA Score (≥2 points) may suggest a high risk of poor outcome in patients with suspected infection",
          "However a positive qSOFA Score alone should not trigger sepsis-directed interventions like initiation of broad spectrum antibiotics. It should instead prompt further investigation of the presence of organ dysfunction or to increase frequency of monitoring ",
          "The Sepsis 3 task force recommends that a positive qSOFA Score should prompt the calculation of a SOFA score to confirm the diagnosis of sepsis"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Seymour CW, Liu VX, Iwashyna TJ, et. al. Assessment of Clinical Criteria for Sepsis For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA. 2016; 315(8):762-774",
          "Rhodes A, Evans LE, Alhazzani W, et. al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock. Crit Care Med. 2017, Mar;45(3):486-552"
        ]
      }
    },
    {
      "id": "child-pugh-score-cirrhosis-mortality",
      "title": "Child-Pugh Score for Cirrhosis Mortality",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Bilirubin",
          "data": {
            "type": "radio",
            "options":
              "<2mg/dL (<34.2µmol/L) | 2-3mg/dL (34.2-51.3µmol/L) | >3mg/dL (>51.3µmol/L)",
            "points": "1/2/3"
          }
        },
        {
          "group": "Albumin",
          "data": {
            "type": "radio",
            "options":
              ">3.5g/dL (>35g/L) | 2.8-3.5g/dL (28-35 g/L) | <2.8 g/dL (<28g/L) ",
            "points": "1/2/3"
          }
        },
        {
          "group": "INR",
          "data": {
            "type": "radio",
            "options": "<1.7 | 1.7-2.2 | >2.2 ",
            "points": "1/2/3"
          }
        },
        {
          "group": "Ascites",
          "data": {
            "type": "radio",
            "options": "Absent | Slight | Moderate",
            "points": "1/2/3"
          }
        },
        {
          "group": "Encephalopathy",
          "data": {
            "type": "radio",
            "options": "No Encephalopathy | Grade 1-2 | Grade 3-4",
            "points": "1/2/3"
          }
        }
      ],
      "results": {
        "5 - 6": [
          "Child Class A; Life expectancy: 15-20 years; Abdominal surgery peri-operative mortality: 10%"
        ],
        "7 - 9": [
          "Child Class B; Indication for transplant evaluation; Abdominal surgery peri-operative mortality: 30%"
        ],
        "10 - 15": [
          "Child Class C; Life expectancy: 1-3 years; Abdominal surgery peri-operative mortality: 82%"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The Child-Pugh Score is used to estimate the severity of cirrhosis",
          "Consider comparing patients with unexpectedly high or low Child scores with another score like the MELD score."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64."
        ]
      }
    },
    {
      "id": "intracranial-bleeding-risk-thrombolytic-therapy-of-mi",
      "title": "Intracranial Bleeding Risk From Thrombolytic Therapy of MI",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Patient is ≥75 years",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient ethnic group is Black",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Female Patient",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Prior history of stroke",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Systolic Blood Pressure ≥ 160 mmHg",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Body weight ≤65kg for Female, ≤80kg for Male patients",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "INR >4 or prothrombin time >24 secs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "TPA used instead of another thrombolytic",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": ["Risk of Cerebral Bleeding: 0.69%"],
        "2": ["Risk of Cerebral Bleeding: 1.02%"],
        "3": ["Risk of Cerebral Bleeding: 1.63%"],
        "4": ["Risk of Cerebral Bleeding: 2.49%"],
        "5 - 8": ["Risk of Cerebral Bleeding: 4.11%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Brass LM, Lichtman JH, Wang Y, et al. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction. Stroke. 2000; 31: 1802-11."
        ]
      }
    },
    {
      "id": "killip-class-heart-failure",
      "title": "Killip Classification for Heart Failure",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Classification",
          "data": {
            "type": "radio",
            "options":
              "No signs of congestion | S3 and Basal rales on auscultation | Acute pulmonary edema | Cardiogenic shock with rales",
            "points": "1/2/3/4"
          },
          "showPoints": false
        }
      ],
      "results": {
        "1": ["Killip Class I: Estimated 30-day mortality: 2-3%"],
        "2": ["Killip Class II: Estimated 30-day mortality: 5-12%"],
        "3": ["Killip Class III: Estimated 30-day mortality: 10-20%"],
        "4": ["Killip Class IV: Estimated 30-day mortality: 10-20%"]
      },
      "showPointsInResults": false,
      "notes": {
        "type": "unordered-list",
        "content": [
          "Killip Classification quantifies the severity of heart failure in patients with Acute Coronary Syndrome and predicts 30-day mortality",
          "Calculator can be used in both STEMI and NSTEMI patients",
          "Mortality rates have declined significantly since the original study published by Killip and Kimball in 1967",
          "30-day mortality estimates are based on Khot 2003 publication which combined Class III/IV due to a smaller number of patients in Class IV (0.3% of patients)"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Killip T, Kimball J. Treatment of myocardial infarction in a coronary care unit. Am J Cardiol. 1967; 20(4):457-64",
          "Khot UN, Jia G, Moliterno DJ et al. Prognostic importance of physical examination for heart failure in non-ST elevation acute coronary syndromes: the enduring value of Killip classification. JAMA. 2003;Oct 22;290(16):2174-81."
        ]
      }
    },
    {
      "id": "mods-score-multiple-organ-dysfunction",
      "title": "MODS Score: Multiple Organ Dysfunction",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "paO2/FiO2 Ratio",
          "data": {
            "type": "radio",
            "options": "300-1000 | 226-299 | 151-225 | 76-150 | 0-75",
            "points": "0/1/2/3/4"
          }
        },
        {
          "group": "Platelet Count (10^3/mm^3)",
          "data": {
            "type": "radio",
            "options": ">120 | 81-120 | 51-80 | 21-50 | ≤20",
            "points": "0/1/2/3/4"
          }
        },
        {
          "group": "Serum Billirubin",
          "data": {
            "type": "radio",
            "options":
              "≤1.2mg/dL or 20µmol/L | 1.3-3.5mg/dL or 21-60µmol/L | 3.6-7.0mg/dL or 6-120µmol/L | 7.0-14mg/dL or 121-240µmol/L | >14mg/dL or 240µmol/L ",
            "points": "0/1/2/3/4"
          }
        },
        {
          "group": "Pressure adjusted heart rate (HR x CVP/MAP)",
          "data": {
            "type": "radio",
            "options": "0-10 | 10.1-15 | 15.1-20 | 20.1-30 | >30",
            "points": "0/1/2/3/4"
          }
        },
        {
          "group": "Glasgow Coma Scale",
          "data": {
            "type": "radio",
            "options": "15 | 13-14 | 10-12 | 7-9 | ≤6",
            "points": "0/1/2/3/4"
          }
        },
        {
          "group": "Serum Creatinine",
          "data": {
            "type": "radio",
            "options":
              "≤1.1mg/dL or 100µmol/L | 1.2-2.2mg/dL or 101-200µmol/L | 2.3-3.9mg/dL or 201-350µmol/L | 4.0-5.7mg/dL or 351-500µmol/L | >5.7mg/dL or 500µmol/L",
            "points": "0/1/2/3/4"
          }
        }
      ],
      "results": {
        "0": ["ICU Mortality 0%, Hospital Mortality 0%, ICU Stay 2 days"],
        "1 - 4": ["ICU Mortality 1-2%, Hospital Mortality 7%, ICU Stay 3 days"],
        "5 - 8": [
          "ICU Mortality 3-5%, Hospital Mortality 16%, ICU Stay 6 days"
        ],
        "9 - 12": [
          "ICU Mortality 25%, Hospital Mortality 50%, ICU Stay 10 days"
        ],
        "13 - 16": [
          "ICU Mortality 50%, Hospital Mortality 70%, ICU Stay 17 days"
        ],
        "17 - 20": [
          "ICU Mortality 75%, Hospital Mortality 82%, ICU Stay 21 days"
        ],
        "21 - 24": ["ICU Mortality 100%, Hospital Mortality 100%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "MODS Score is used to determine ICU and hospital mortality and average ICU stay for patients with multiple organ failure",
          "Ratio between partial pressure of Oxygen and Fraction of inspired Oxyygen is measured directly for patients undergoing mechanical ventilation and is estimated for non-ventilated patients",
          "A simplified version of the MODS Score can be found in the modified Marshall score which uses the diagnosis capacity for organ failure to assess the severity of acute pancreatitis"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Marshall JC, Cook DJ, Christou NV, et. al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 Oct;23(10):1638-52. Review.",
          "Nawaz H, Mounzer R, Yadav D, Yabes JG, Slivka A, Whitcomb DC, Papachristou GI. (2013) Revised Atlanta and determinant-based classification: application in a prospective cohort of acute pancreatitis patients. Am J Gastroenterol; 108(12):1911-7.",
          "Jacobs S, Zuleika M, Mphansa T. (1999) The Multiple Organ Dysfunction Score as a descriptor of patient outcome in septic shock compared with two other scoring systems. Crit Care Med; 27(4):741-4."
        ]
      }
    },
    {
      "id": "centor-score-strep-pharyngitis",
      "title": "Centor Score for Strep Pharyngitis (Modified McIsaac)",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Age range",
          "data": {
            "type": "radio",
            "options": "3-14 yrs | 15-44 yrs | ≥45yrs",
            "points": "1/0/-1"
          }
        },
        {
          "group": "Exudate or swelling on tonsils",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Tender/Swollen anterior cervical lymph nodes",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Temp >38ºC (100.4ºF)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Cough",
          "data": {
            "type": "radio",
            "options": "Present | Absent",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "-1 - 0": [
          "1%-2.5% likelihood of Strep Pharyngitis; No further testing nor antibiotics"
        ],
        "1": [
          "5%-10% likelihood of Strep Pharyngitis; No further testing nor antibiotics"
        ],
        "2": [
          "11%-17% likelihood of Strep Pharyngitis; Optional rapid strep testing and/or culture"
        ],
        "3": [
          "28%-35% likelihood of Strep Pharyngitis; Consider rapid strep testing and/or culture. IDSA and ASIM no longer recommend empiric treatment for strep based on symptoms alone"
        ],
        "4 - 5": [
          "51%-53% likelihood of Strep Pharyngitis; Consider rapid strep testing and/or culture. IDSA and ASIM no longer recommend empiric treatment for strep based on symptoms alone"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Centor Score estimates the probability that pharyngitis is streptococcal to help determine which patients to test first",
          "Use this only in patients with recent onset (≤3days) of acute pharyngitis",
          "Most pharyngitis is viral and does not respond to antibiotic treatment",
          "Steroids and NSAIDs can improve symptoms; antibiotics are often indicated in streptococcal pharyngitis but do not prevent the suppurative complications of it like peritonsillar abscess"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Centor RM, Witherspoon JM, Dalton HP, Brody CE, Link K. The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1981;1(3):239-46.",
          "McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. CMAJ. 1998 Jan 13;158(1):75-83."
        ]
      }
    },
    {
      "id": "perc-rule-pulmonary-embolism",
      "title": "PERC Rule for Pulmonary Embolism",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Age ≥ 50yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Heart Rate ≥ 100bpm",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "SaO2 in room air <95%",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Unilateral leg swelling",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Hemoptysis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Recent surgery or trauma",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Prior Pulmonary Embolism or Deep Vein Thrombosis",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Hormone use (e.g. oral contraceptives, hormone replacement therapy)",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": [
          "No need for further workup; <2% chance of PE. If no criteria is positive and doctor's pre-test probability is ≤15% then the PERC Rule criteria are satisfied"
        ],
        "1 - 8": [
          "If any criteria are positive then the PERC Rule cannot be used to rule out PE in this patient"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "PERC Rule helps to rule out Pulmonay Embolism if no criteria are present and pre-test probability is ≤15%",
          "If there is a low risk patient who is not PERC negative, consider a d-dimer for further evaluation",
          "If the d-dimer test is negative and clinical gestalt determines a pre-test probability is ≤15% then the patient does not require further testing for PE",
          "If the d-dimer test is positive, further testing such as CT-angiogram or a V/Q scan should be performed"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004 Aug;2(8):1247-55.",
          "Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC, Richman PB, O'Neil BJ, Nordenholz K. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008 May;6(5):772-80."
        ]
      }
    },
    {
      "id": "ada-diabetes-risk-calculator",
      "title": "ADA Diabetes Risk Calculator",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Patient Age",
          "data": {
            "type": "radio",
            "options": "<40 yrs | 40-49 yrs | 50-59 yrs | ≥60 yrs",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "Gender",
          "data": {
            "type": "radio",
            "options": "Female | Male",
            "points": "0/1"
          }
        },
        {
          "group": "Gestational Diabetes (Female Patients Only)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group":
            "Hypertension (History of Hypertension and/or BP≥140/90 mmHg)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "First degree relative with Diabetes",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Physically active",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "BMI",
          "data": {
            "type": "radio",
            "options": "<25 | 25-30 | 30-39 | ≥40",
            "points": "0/1/2/3"
          }
        }
      ],
      "results": {
        "1 - 4": [
          "Not high risk. T2DM screening not recommended by ADA guidelines."
        ],
        "5 - 10": [
          "High risk. Patient should be formally screened for diabetes per ADA guidelines"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "American Diabetes Association: Classification and Diagnosis of Diabetes. Diabetes Care. 2016 Jan;39 Suppl 1:S13-22",
          "Bang H, Edwards AM, Bomback AS, et al. Development and Validation of a Patient Self-assessment Score for Diabetes Risk .Ann Intern Med. 2009;151(11):775-783."
        ]
      }
    },
    {
      "id": "fall-risk-elderly-hospitalized-patients",
      "title": "Fall Risk in Elderly Hospitalized Patients",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label":
                "History of fall at presentation or fall since admission",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient displays agitation",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Visually impaired",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Frequent urination",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient has poor mobility",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": ["Risk of falling: 2.4-4.1%"],
        "2 - 5": ["Risk of falling: 42 to 65.3%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Oliver D, Britton M, Seed P, et. al. Development and evaluation of evidence based risk assessment tool (STRATIFY) to predict which elderly inpatients will fall: case-control and cohort studies. BMJ. 1997 Oct 25;315(7115):1049-1053."
        ]
      }
    },
    {
      "id": "abc-score-massive-blood-transfusion",
      "title": "ABC Score for Massive Blood Transfusion",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label": "Penetrating Mechanism?",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Systolic BP ≥90mmHg?",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Heart Rate ≥120bpm?",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Positive Ultrasound FAST Exam?",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 1": [
          "Less likely to require a massive transfusion (i.e. ≥10 units of packed RBCs)"
        ],
        "2 - 4": [
          "Likely to require massive blood transfusion (i.e. ≥10 units of packed RBCs)"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Massive transfusion protocols are specific to institution but often are 1:1:1 or 1:1:2 for fresh frozen plasma, platelets and packed Red Blood Cells (JAMA 2015)",
          "The ABC Score helps to predict if trauma patients should receive blood through a massive transfusion protocol but it does not indicate if trauma patients should receive blood"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Nunez TC, Voskresensky IV, Dossett LA, Shinall R, Dutton WD, Cotton BA. Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)? J Trauma. 2009 Feb;66(2):346-52.",
          "Cotton BA, Dossett LA, Haut ER, Shafi S, Nunez TC, Au BK, Zaydfudim V, Johnston M, Arbogast P, Young PP. Multicenter validation of a simplified score to predict massive transfusion in trauma. J Trauma. 2010 Jul;69 Suppl 1:S33-9."
        ]
      }
    },
    {
      "id": "acute-gout-diagnosis-rule",
      "title": "Acute Gout Diagnosis Rule",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label": "Male",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "History of Arthritis attack",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "Onset ≤1 day",
              "points": "0.5"
            },
            {
              "type": "checkbox",
              "label": "Joint redness",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "1st metatarsophalangeal joint involvement",
              "points": "2.5"
            },
            {
              "type": "checkbox",
              "label":
                "Hypertension or Cardiac Disease (e.g. MI, Stroke, PVD, CHF, Angina)",
              "points": "1.5"
            },
            {
              "type": "checkbox",
              "label": "Serum uric acid > 0.35 mmol/L or 5.88 mg/dL",
              "points": "3.5"
            }
          ]
        }
      ],
      "results": {
        "0 - 4": [
          "Gout is unlikely. Estimated prevalence of gout is 2.2% in original study"
        ],
        "4.5 - 7.5": [
          "Estimated prevalence of gout is 31.2%. Patients often benefit the most from synovial fluid analysis for urate crystals"
        ],
        "8 - 13": [
          "Gout arthritis is very likely. Estimated prevalence of gout is 82.5%. Consider starting gout medications. "
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Gout flares are often treated with some combination of steroids, NSAIDS (classically, indomethacin), opioids for extreme pain, and colchicine.",
          "Management will depend on the patient's age and other risk factors for complications.",
          "After the initial flare, patients may benefit from urate-lowering therapies like allopurinol.",
          "This rule was developed and validated in Europe and may be less applicable to non-European populations"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Hein J. E. M. Janssens, Jaap Fransen, Eloy H. van de Lisdonk, et al. A Diagnostic Rule for Acute Gouty Arthritis in Primary Care Without Joint Fluid Analysis. Arch Intern Med. 2010;170(13):1120-1126",
          "Keinhorst L, Janssens HJM, Fransen J., Janssen M.Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study: Reply. Rheumatology (Oxford). 2015 APr;54(4):609-14 "
        ]
      }
    },
    {
      "id": "bishop-score-vaginal-delivery-labor",
      "title": "Bishop Score for Vaginal Delivery and Induction of Labor",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Dilation",
          "data": {
            "type": "radio",
            "options": "Closed | 1-2cm | 3-4cm | ≥5cm",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "Effacement",
          "data": {
            "type": "radio",
            "options": "0-30% | 40-50% | 60-70% | ≥80%",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "Station",
          "data": {
            "type": "radio",
            "options": "-3 | -2 | -1,0 | +1,+2",
            "points": "0/1/2/3"
          }
        },
        {
          "group": "Position",
          "data": {
            "type": "radio",
            "options": "Posterior | Mid-Position | Anterior",
            "points": "0/1/2"
          }
        }
      ],
      "results": {
        "1 - 5": [
          "Unfavorable cervix. Induction may be necessary for successful vaginal delivery"
        ],
        "6 - 7": [
          "No definitive prediction on whether induction will be successful. Consider induction or augmentation of labor based on clinical judgement"
        ],
        "8 - 13": [
          "Spontaneous vaginal delivery is more likely. Augmentation and induction may be unnecessary"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Bishop Score helps to predict the likelihood of successful vaginal delivery",
          "Induction is often considered at Bishop Score ≤ 5 points"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol. 1964 Aug;24:266-8.",
          "Newman RB et al. Preterm prediction study: comparison of the cervical score and Bishop score for prediction of spontaneous preterm delivery. Obstet Gynecol. 2008 Sep;112(3):508-15"
        ]
      }
    },
    {
      "id": "chalice-rule-child-head-injury",
      "title": "CHALICE Rule for Child Head Injury",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "History",
          "data": [
            {
              "type": "checkbox",
              "label": "Witnessed LOC > 5min",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Amnesia > 5min",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Abnormal drowsiness",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "≥3 vomit episodes after head injury",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Suspicion of non-accidental injury",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Seizure after head injury (no previous Epilepsy history)",
              "points": "1"
            }
          ]
        },
        {
          "group": "Examination",
          "data": [
            {
              "type": "checkbox",
              "label": "Glasgow Coma Scale <14 (or GCS <15 if <1 yr old)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Suspicion of penetrating or depressed skull injury",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Signs of basal skull fracture (e.g. Blood or CSF from ear or nose, Panda eyes, Serious facial injury)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Positive focal neurologic sign",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Bruises, swelling or laceration >5cm (if <1 yr old)",
              "points": "1"
            }
          ]
        },
        {
          "group": "Mechanism",
          "data": [
            {
              "type": "checkbox",
              "label":
                "High speed road accident (> 64kmph/40mph) as pedestrian, cyclist or car occupant",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Fall of >3m in height",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "High speed injury from a projectile or object",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": ["Low risk of intracranial pathology. CT not necessary"],
        "1 - 14": ["Not low risk. Consider CT"]
      },
      "notes": [
        {
          "type": "unordered-list",
          "content": [
            "Use in children <16 years with history or signs of head injury",
            "Consider the PECARN Pediatric Head Injury score as it is the most widely validated"
          ]
        }
      ],
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Dunning J, Daly JP, Lomas JP, Lecky F, Batchelor J, Mackway-Jones K, Derivation of the children's head injury algorithm for the prediction of important clinical events decision rule for head injury in children.Arch Dis Child. 2006 Nov;91(11):885-91."
          ]
        }
      ]
    },
    {
      "id": "burch-wartofsky-point-scale-thyrotoxicosis",
      "title": "Burch-Wartofsky Point Scale for Thyrotoxicosis",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Temperature",
          "data": {
            "type": "radio",
            "options":
              "37.2-37.7°C (99-99.9°F) | 37.8-38.2°C (100-100.9°F) | 38.3-38.8°C (101-101.9°F) | 39.3-39.9°C (103-103.9°F) | ≥40°C (≥104°F)",
            "points": "5/10/15/20/25/30"
          }
        },
        {
          "group": "Central Nervous System Effects",
          "data": {
            "type": "radio",
            "options":
              "Absent | Mild (Agitation) | Moderate (Seizures, coma) | Severe (Seizures, coma)",
            "points": "0/10/20/30"
          }
        },
        {
          "group": "Gastrointestinal-hepatic dysfunction",
          "data": {
            "type": "radio",
            "options":
              "Absent | Moderate (Diarrhea, Nausea/vomiting, Abdominal pain) | Severe (Unexplained jaundice)",
            "points": "0/10/15"
          }
        },
        {
          "group": "Congestive Heart Failure",
          "data": {
            "type": "radio",
            "options":
              "Absent | Mild (Pedal Edema) | Moderate (Bibasilar rales) | Severe (Pulmonary Edema)",
            "points": "0/5/10/15"
          }
        },
        {
          "group": "Heart Rate",
          "data": {
            "type": "radio",
            "options":
              "90-109 bpm | 110-119 bpm | 120-129 bpm | 130-139 bpm | ≥140 bpm",
            "points": "5/10/15/20/25"
          }
        },
        {
          "group": "Atrial Fibrillation",
          "data": {
            "type": "radio",
            "options": "None | Present",
            "points": "0/10"
          }
        },
        {
          "group": "Precipitating Event",
          "data": {
            "type": "radio",
            "options": "None | Yes",
            "points": "0/10"
          }
        }
      ],
      "results": {
        "10 - 24": [
          "Unlikely to represent thyroid storm. Investigate diagnosis of thyrotoxicosis and obtain additional imaging (e.g. thyroid ultrasound, radioactive iodine uptake and scan)"
        ],
        "25 - 44": [
          "Impending thyroid storm. Consider thionamides and symptom management along with ICU monitoring"
        ],
        "45 - 140": [
          "Highly suggestive of thyroid storm. Consider rapid and aggressive multimodal management in ICU"
        ]
      },
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993 Jun;22(2):263-77."
          ]
        }
      ]
    },
    {
      "id": "mmrc-dyspnea-scale",
      "title": "mMRC Dyspnea Scale",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Symptom severity",
          "data": {
            "type": "radio",
            "options":
              "Dyspnea only with strenuous exercise | Dyspnea when hurrying or walking up a slight hill | Walks slower than people of similar age due to dyspnea or has to stop for breath when walking at own pace | Stops for breath after walking 91m (100 yards) or after a few min | Too dyspneic to leave house or breathless when dressing",
            "points": "0/1/2/3/4"
          }
        }
      ],
      "results": {
        "0": ["Grade 0"],
        "1": ["Grade 1"],
        "2": ["Grade 2"],
        "3": ["Grade 3"],
        "4": ["Grade 4"]
      },
      "notes": [
        {
          "type": "unordered-list",
          "content": [
            "The mMRC Dyspnea scale is best used to establish baseline functional impairment caused by dyspnea",
            "The mMRC is correlated with morbidity and mortality for patients with respiratory disease, but there is no evidence that confirms attributable cause and effect between mMRC Dyspnea scale scores and patient centered outcomes",
            "The score must be contextualized with an individual patient's history, physical and available diagnostic test results",
            "For patients with higher mMRC grade ≥2 and clinical findings consistent with respiratory disease, consider spirometry (FEV1 and FVC), determining the patient's BODE index and/or GOLD stage as well as targeted diagnostic and/or therapeutic interventions"
          ]
        }
      ],
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Mahler DA, Wells CK, Evaluation of clinical methods for rating dyspnea. Chest. 1988 Mar;93(3):580-6",
            "Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir. Crit. Care Med. 1998 Oct;158(4):1185-9."
          ]
        }
      ]
    },
    {
      "id": "rule-of-sevens-lyme-meningitis",
      "title": "Rule of 7s for Lyme Meningitis",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Number of days of headache",
          "data": {
            "type": "radio",
            "options": "<7 | ≥7",
            "points": "0/1"
          }
        },
        {
          "group": "CSF Mononuclear cells",
          "data": {
            "type": "radio",
            "options": "<70% | ≥70%",
            "points": "0/1"
          }
        },
        {
          "group": "7th (or other) Cranial Nerve Palsy",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0": [
          "Low risk for Lyme Meningitis. Antibiotics not recommended, consider close patient follow-up and use clinical judgement regarding patient disposition"
        ],
        "1 - 3": [
          "Not low risk for Lyme Meningitis. Consider antibiotics to cover Borrelia burgdoreferi"
        ]
      },
      "notes": [
        {
          "type": "unordered-list",
          "content": [
            "Rule of 7s is used to assist in distinguishing Lyme meningitis from aseptic meningitis and to start antibiotics for suspected Lyme",
            "Use in pediatric patients (2-18 years) in a Lyme endemic area with CSF pleocytosis, defined as CSF WBC ≥ 10 cells/mm^3 (corrected for CSF RBC if >500 using a ratio of 1 WBC for every 500 RBC)"
          ]
        }
      ],
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Garro AC, Rutman M, Simonsen K, Jaeger JL, Chapin K, Lockhart G. Prospective validation of a clinical prediction model for Lyme meningitis in children. Pediatrics. 2009 May;123(5):e829-34.",
            "Cohn KA, Thompson AD, et al. Validation of a Clinical Prediction Rule to Distinguish Lyme Meningitis From Aseptic Meningitis. Pediatrics. 2012; 129(1):e46-53"
          ]
        }
      ]
    },
    {
      "id": "san-francisco-syncope-rule",
      "title": "San Francisco Syncope Rule",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "History of Congestive Heart Failure",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Hematocrit <30%",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Abnormal ECG (Non-sinus rhythm or ECG changed)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Shortness of Breath",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Systolic BP <90 mmHg at triage",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0": ["Patient is in low-risk group for serious outcome"],
        "1 - 5": [
          "Patient is not in the low-risk group for serious outcome (96% sensitivity, 62% specificity); Negative predictive value 99.2%, Positive predictive value 24.8%"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Use the SF Syncope Rule to stratify the risk of patients with unexplained syncope",
          "Serious outcome in this study is defined as death, myocardial infarction, arrhythmia, pulmonary embolism, stroke, subarachnoid hemorrhage, significant hemorrahge or any condition causing a return Emergency Department visit and hospitalization for a related event"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Quinn J, McDermott D, Stiell I, Kohn M, Wells G. Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes. Ann Emerg Med. 2006 May;47(5):448-54.",
          "Birnbaum A, Esses D, Bijur P, Wollowitz A, Gallagher EJ. Failure to validate the San Francisco Syncope Rule in an independent emergency department population. Ann Emerg Med. 2008 Aug;52(2):151-9."
        ]
      }
    },
    {
      "id": "pediatric-appendicitis-score",
      "title": "Pediatric Appendicitis Score",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "RLQ tenderness to cough, percussion or hopping",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Anorexia",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Nausea or vomiting",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Fever ≥38°C or 100.4°F",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Tenderness over right iliac fossa",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/2"
          }
        },
        {
          "group": "Leukocytosis WBC >10,000",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Migration of pain to Right Lower Quadrant",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Left shift Absolute Neutrophil Count >7500",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0 - 3": ["Appendicitis is unlikely. Consider other diagnoses"],
        "4 - 6": [
          "Cannot definitively rule in or rule out appendicitis. Consider ultrasound or MRI imaging and/or surgical consult"
        ],
        "6 - 10": [
          "Appendicitis is likely. Consider surgical consult and imaging; Patients should only undergo ultrasound prior to surgical consult"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "PAS Score can be used to estimate risk of appendicitis in children",
          "For patients who are not at low risk, next steps include NPO status, IV fluids, analgesia and imaging or surgical consult",
          "Patients in low risk group according to the PAS do not have a zero risk. Use clinical judgement if imaging or surgical consult may aid in diagnosis"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Samuel M. Pediatric Appendicitis Score. Journal of Pediatric Surgery, Vol 37; No6(June), 2002:pp 877-881",
          "Goldman RD. The Paediatric Appendicitis Score (PAS) was useful in children with acute abdominal pain. Evid Based Med 2009; 14:26"
        ]
      }
    },
    {
      "id": "dragon-score-post-tpa-stroke-outcome",
      "title": "DRAGON Score for Post-TAP Stroke Outcome",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "HyperDense Cerebral Artery/Early Infarct on CT scan",
          "data": {
            "type": "radio",
            "options": "No | Either | Both",
            "points": "0/1/2"
          }
        },
        {
          "group": "Modified Rankin Scale >1, Prestroke",
          "data": {
            "type": "radio",
            "options": "No | Either",
            "points": "0/1"
          }
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "<65 yrs | 65-79 yrs | ≥80 yrs",
            "points": "0/1/2"
          }
        },
        {
          "group": "Onset of Treatment >90 min",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Glucose at Baseline >8mmol/L (144 mg/dL)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Baseline NIH Stroke Scale",
          "data": {
            "type": "radio",
            "options": "0-4 | 5-9 | 10-15 | ≥16",
            "points": "0/1/2/3"
          }
        }
      ],
      "results": {
        "0 - 1": [
          ">99% likelihood of a good outcome (mRS 0-2); 0% likelihood of a miserable outcome (mRS 5-6)"
        ],
        "2": [
          ">96% likelihood of a good outcome (mRS 0-2); 2% likelihood of a miserable outcome (mRS 5-6)"
        ],
        "3": [
          ">87% likelihood of a good outcome (mRS 0-2); 7% likelihood of a miserable outcome (mRS 5-6)"
        ],
        "4": [">81% likelihood of a good outcome (mRS 0-2)"],
        "5": [">83% likelihood of a miserable outcome (mRS 5-6)"],
        "6": [">90% likelihood of a miserable outcome (mRS 5-6)"],
        "7": [">97% likelihood of a miserable outcome (mRS 5-6)"],
        "8 - 10": [
          "0% likelihood of a good outcome (mRS 0-2); >99% likelihood of a miserable outcome (mRS 5-6)"
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "The DRAGON Score is used to predict 3 month outcomes in ischemic stroke patients receiving intravenous thrombolysis (tPA)",
          "For patients with a DRAGON score that predicts a miserable outcome even if tPA is given, consider the risk/benefit of giving IV thrombolytics",
          "These patients may be potential candidates for endovascular thrombectomy, although the benefits of this procedure have not yet been demonstrated in literature"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Strbian D, Meretoja A, Ahlhelm FJ, Pitkäniemi J, Lyrer P, Kaste M, Engelter S, Tatlisumak T. Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score. Neurology. 2012 Feb 7;78(6):427-32.",
          "Strbian D, Seiffge DJ, Breuer L, et al. Validation of the DRAGON Score in 12 Stroke Centers in Anterior and Posterior Circulation.Stroke. 2013;STROKEAHA.113.002033"
        ]
      }
    },
    {
      "id": "vancouver-chest-pain-rule",
      "title": "Vancouver Chest Pain Rule",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Step 1:"
        },
        {
          "group":
            "Abnormal initial ECG (e.g. ST elevation, ST depression >0.5mm, Q waves, LVH, paced rhythm or LBBB)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          },
          "showPoints": false
        },
        {
          "group": "Positive troponin at 2 hours",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          },
          "showPoints": false
        },
        {
          "group": "Prior ACS or nitrate use",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          },
          "showPoints": false
        },
        {
          "group": "Step 2 (Only if Step 1 answers are all No):"
        },
        {
          "group": "Does palpation reproduce pain?",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/4"
          },
          "showPoints": false
        },
        {
          "group": "Step 3 (Only if Step 2 answer is No):"
        },
        {
          "group": "Age ≥50 years",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          },
          "showPoints": false
        },
        {
          "group": "Does pain radiate to neck, jaw or left arm?",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "5/5"
          },
          "showPoints": false
        }
      ],
      "results": {
        "0": ["Low risk for adverse event. Candidate for early discharge"],
        "1 - 3": [
          "Standard Evaluation. This patient is not a candidate for early discharge and should receive a standard chest pain evaluation"
        ],
        "4": [
          "Low risk if chest pain is reproducible. Candidate for early discharge. Step 3 is not required."
        ],
        "5 - 10": [
          "Standard Evaluation. This patient is not a candidate for early discharge and should receive a standard chest pain evaluation"
        ]
      },
      "showPointsInResults": false,
      "notes": {
        "type": "unordered-list",
        "content": [
          "Vancouver Chest Pain Rule identifies chest pain patients who are at low risk and candidates for early discharge",
          "If the answers to Step 1 are no to all, move to Step 2. Otherwise proceed with chest pain evaluation",
          "If the answer to Step 2 is yes, proceed to early discharge. If no, move to Step 3",
          "If the answers to Step 3 are no to all, proceed to early discharge. If not, proceed with chest pain evaluation"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Scheuermeyer FX, Wong H, Yu E, Boychuk B, Innes G, Grafstein E, Gin K, Christenson J.Development and validation of a prediction rule for early discharge of low-risk emergency department patients with potential ischemic chest pain. CJEM. 2014 Mar;16(2):106-19."
        ]
      }
    },
    {
      "id": "behcets-syndrome-diagnostic-criteria",
      "title": "Bechet's Syndrome Diagnostic Criteria",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Recurrent oral ulcerations: minor aphthous, major aphtous or herpetiform ulceration observed by physician or patient, which recurred at least 3 times in one 12 month period",
              "points": "1"
            }
          ]
        },
        {
          "group": "Minor Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Eye lesion: anterior uveitis, posterior uveitis, or cells in vitreous on slit lamp examination or retinal vasculitis observed by ophthalmologist",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Recurrent genital ulceration: aphthous ulceration or scarring observed by physician or patient",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Skin lesions: erythema nodosum observed by physician or patient, pseudofolliculitis or papulopustular lesions, or acneform nodules observed by physician in post-adolescent patients not on corticosteroid treatment",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, rheumatoid factor",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Positive pathergy test (Behcetine test) read by physician 24-48 hours",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": ["Diagnostic : 1 Required Criteria and 2 Minor Criteria"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990 May 5;335(8697):1078-80."
        ]
      }
    },
    {
      "id": "kawasaki-disease-diagnostic-criteria",
      "title": "Kawasaki Disease Diagnostic Criteria",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Fever for at least five days generally high and spiking (often to 40° C or more), persisting for one to two weeks or longer in untreated patients.",
              "points": "1"
            }
          ]
        },
        {
          "group": "Additional Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Acute changes in arms or legs: redness, swelling and erythema of the palms and soles.",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Polymorphic exanthem involving the trunk and extremities.",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Painless, nonexudative bilateral bulbar conjunctival injection",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Changes in lips and oral cavity. Strawberry tongue, redness and cracking of the lips, and erythema of the oropharyngeal mucosa. No mouth ulcers.",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Cervical lymphadenopathy: often unilateral, slightly tender, firm nodes >1.5cm in diameter.",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Exclusion of other diseases with similar findings",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Diagnostic : 1 Required Criteria and 4 Additional Criteria"
        ]
      },
      "notes:": {
        "type": "unordered-list",
        "content": [
          "Use to diagnose pediatric patients with several days of unexplained fever associated with any of the principal clinical features of Kawasaki Disease",
          "If the diagnosis of Kawasaki Disease is made in the acute phase, prompt treatment is essential with intravenous immunoglobulin (IVIG) and aspirin to prevent CA abnormalities",
          "Treatment should be initiated within the first 10 days of the disease and if possible within 7 days of the disease"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-80.",
          "Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004 Oct 26;110(17):2747-71."
        ]
      }
    },
    {
      "id": "irritable-bowel-syndrome-diagnostic-criteria-manning",
      "title":
        "Irritable Bowel Syndrome Diagnostic Criteria (Manning Criteria)",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Persistence or recurrence of the following symptoms for at least 3 months time: Abdominal pain / discomfort, relieved with BM or associated with a change in the frequency or consistency of stool",
              "points": "1"
            }
          ]
        },
        {
          "group": "Additional Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "A varying or irregular pattern of defecation at least 25% of the time with 2 or more of the following:",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Altered Bowel Movement frequency",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Altered Bowel Movement form (hard, loose or watery stool)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Altered stool passage (straining, urgency, or incomplete evacuation sensation)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Diarrhea with mucus >25% of the time",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Diagnostic : 1 Required Criteria and 2 Additional Criteria"
        ]
      },
      "notes:": {
        "type": "unordered-list",
        "content": [
          "Manning Criteria determines the likelihood of irritable bowel syndrome diagnosis",
          "IBS is a rule-out diagnosis which means that all other possibilities must be ruled out first",
          "If red flag signs are present, IBS is not likely. These include: patient's age >50 years, weight loss, blood in stools, anemia and fever"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Drossman DA, Funch-Jensen P, Janssens J, et al. Identification of subgroups of functional bowel disorders. Gastroenterol International. 1990;3:15."
        ]
      }
    },
    {
      "id": "multiple-myeloma-diagnostic-criteria",
      "title": "Multiple Myeloma Diagnostic Criteria",
      "type": "formula",
      "questions": [
        {
          "group": "Major Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Plasmacytoma on tissue biopsy",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Bone marrow plasmacytosis of > 30%",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "M Protein: IgG > 3.5 g/L; IgA > 2.0 g/L",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Urinary kappa or lambda chain excretion of > 1g / 24 hours in absence of amyloidosis",
              "points": "1"
            }
          ]
        },
        {
          "group": "Minor Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Marrow plasmacytosis of 10-30%",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Evidence of a monoclonal protein but lessor amounts than above",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Lytic bone lesions",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Hypoglobulinemia of normal proteins: IgM < 500 mg/L, IgA < 1 g/L or IgG < 6g/L",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Diagnostic: 1 Major Criteria and 1 Minor Criteria",
          "Diagnostic: 0 Major Criteria and 3 Minor Criteria"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975; 36:842-854."
        ]
      }
    },
    {
      "id": "bacterial-meningitis-score-children",
      "title": "Bacterial Meningitis Score for Children",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "CSF Gram Stain Positive",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "CSF Absolute Neutrophil Count ≥1000 cells/µL",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "CSF protein ≥80 mg/dL (800 mg/L)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group":
            "Peripheral blood Absolute Neutrophil Count ≥10,000 cells/µL",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Seizure at or prior to initial presentation",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Leukocytosis WBC >10,000",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0": [
          "Very low risk for bacterial meningitis. Consider discharge with close follow-up within 24-48 hr"
        ],
        "1 - 6": [
          "Not very low risk for bacterial meningitis. Consider admission for parenteral antibiotics and observation while awaiting CSF culture results."
        ]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "This calculator can be used on pediatric patients (aged 29 days to 19 years) with suspected meningitis to rule out bacterial meningitis",
          "Do not use on patients who are critically ill requiring respiratory or vasopressor support, or who have received antibiotics <72h prior to lumbar puncture",
          "Do not use on patients with a Ventriculoperitoneal shunt or recent neurosurgery or are immunosuppressed",
          "Do not use on patients who have known active Lyme Disease or proof or another bacterial infection (e.g. UTI, bone infection, bacteremia) that requires antibiotic therapy"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Nigrovic LE, Kupperman N, Macias CG, Cannavino CR et al. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA. 2007 Jan 3;297(1):52-60.",
          "Nigrovic LE, Malley R, Kuppermann N. Meta-analysis of bacterial meningitis score validation studies. Arch Dis Child. 2012 Sep;97(9):799-805."
        ]
      }
    },
    {
      "id": "ottawa-foot-rule-for-the-use-of-x-ray-in-foot-injury",
      "title": "Ottawa Foot Rule for the Use of X-Ray in Foot Injury",
      "type": "formula",
      "questions": [
        {
          "group": "Required Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label": "Pain in the midfoot",
              "points": "1"
            }
          ]
        },
        {
          "group": "Major Criteria",
          "showPoints": false,
          "data": [
            {
              "type": "checkbox",
              "label":
                "Inability to bear weight right after the injury as well as in the emergency department (4 steps)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Bone tenderness at the navicular or the base of the fifth metatarsal",
              "points": "1"
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "X-Ray Indicated : 1 Required Criteria and 1 Major Criteria"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Stiell IG, McKnight RD, Greenberg GH, et. al. Implementation of the Ottawa ankle rules. JAMA. 1994 Mar 16;271(11):827-832.",
          "Stiell IG, Greenberg GH, McKnight RD, et.al. Decision rules for the use of radiography in acute ankle injuries. Refinement and prospective validation. . JAMA. 1993 Mar 3;269(9):1127-32.",
          "Stiell IG, Greenberg GH, McKnight RD, et. al. A study to develop clinical decision rules for the use of radiography in acute ankle injuries. Ann Emerg Med. 1992 Apr;21(4):384-90."
        ]
      }
    },
    {
      "id": "ottawa-knee-rule-x-ray-knee-injury",
      "title": "Ottawa Knee Rule for use of X-Ray in Knee Injury",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label": "Age ≥ 55yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Isolated tenderness of patella (no bone tenderness of knee other than patella)",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Tenderness of head of fibula",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Inability to flex to 90°",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Inability to bear weight both immediately and in the Emergency department for 4 steps",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": ["X-Ray not indicated"],
        "1 - 6": ["X-Ray is indicated"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "Ottawa Knee Rule describes criteria for low risk knee trauma patients that do not require knee imaging ",
          "Patients who do not have any of the Ottawa Knee Rules criteria present do not require an X-Ray. If one or more of the criteria is met, then an X-Ray is recommended."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Stiell IG, Greenberg GH, Wells GA, et. al. Prospective validation of a decision rule for the use of radiography in acute knee injuries. JAMA. 1996 Feb 28;275(8):611-615.",
          "Stiell IG, Wells GA, McDowell I, et. al. Use of radiography in acute knee injuries: need for clinical decision rules. Acad Emerg Med. 1995 Nov;2(11):966-73."
        ]
      }
    },
    {
      "id": "rockall-score-upper-gi-bleeding",
      "title": "Rockall Score for Upper GI Bleeding",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Patient Age",
          "data": {
            "type": "radio",
            "options": "<60 years | 60-79 years | ≥80 years",
            "points": "0/1/2"
          }
        },
        {
          "group": "Shock",
          "data": {
            "type": "radio",
            "options":
              "No shock | Tachycardia (SBP≥100mmHg and HR≥100bpm) | Hypotension (SBP<100mmHg)",
            "points": "0/1/2"
          }
        },
        {
          "group": "Co-morbidities",
          "data": {
            "type": "radio",
            "options":
              "No major co-morbidity | Any co-morbidity except renal failure, liver failure and/or disseminated malignancy | Renal failure, Liver failure, and/or disseminated malignancy",
            "points": "0/2/3"
          }
        },
        {
          "group": "Diagnosis",
          "data": {
            "type": "radio",
            "options":
              "Mallory-Weiss tear | No lesion identified and no stigmata of recent hemorrhage | All other diagnoses | Malignancy of upper GI tract",
            "points": "0/0/1/2"
          }
        },
        {
          "group": "Major stigmata of recent hemorrhage",
          "data": {
            "type": "radio",
            "options":
              "None | Dark spot only | Blood in upper GI tract | Adherent clot | Visibile or spurting vessel",
            "points": "0/0/2/2/2"
          }
        }
      ],
      "results": {
        "0": ["Low risk; 4.9% rebleeding risk with 0% mortality risk"],
        "1": ["Low risk, 3.4% rebleeding risk with 0% mortality risk"],
        "2": ["Moderate risk 5.3% rebleeding risk with 0.2% mortality risk"],
        "3": ["Moderate risk 11.2% rebleeding risk with 2.9% mortality risk"],
        "4": ["Moderate risk 14.1% rebleeding risk with 5.3% mortality risk"],
        "5": ["High risk 24.1% rebleeding risk with 10.8% mortality risk"],
        "6": ["High risk 32.9% rebleeding risk with 17.3% mortality risk"],
        "7": ["High risk 43.8% rebleeding risk with 27% mortality risk"],
        "8 - 11": ["High risk 41.8% rebleeding risk with 41.1% mortality risk"]
      },
      "notes": [
        {
          "type": "unordered-list",
          "content": [
            "Rockall Score is used for known upper GI bleed patients with a completed endoscopy",
            "Patients who have not yet had endoscopy should be assessed wiht the Pre-Endoscopy Rockall Score",
            "The Rockall score predicts mortality better than chance alone but should be interpreted with caution. Other scores such as the Glasgow-Blatchford Score may perform better especially for identifying very low risk patients.",
            "Consider diagnostic endoscopy for patients with high risk of mortality from upper GI bleeding",
            "Consider ICU care for patients who are hemodynamically unstable from upper GI bleeding"
          ]
        }
      ],
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinall haemorrhage. Gut. 1996 Mar;38(3):316-21.",
            "Vreeburg EM, Terwee CB, et al. Validation of the Rockall risk scoring system in up per gastrointestinal bleeding. Gut 1999;44:331-335"
          ]
        }
      ]
    },
    {
      "id": "aims65-score-upper-gi-bleeding",
      "title": "AIMS65 Score for Upper GI Bleeding Mortality",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Albumin <3g/dL (30g/L)",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "INR >1.5",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Alteration in mental status",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Systolic BP ≤90mmHg",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        },
        {
          "group": "Age ≥65 years",
          "data": {
            "type": "radio",
            "options": "No | Yes",
            "points": "0/1"
          }
        }
      ],
      "results": {
        "0": ["0.3% in-hospital mortality risk"],
        "1": ["1.2% in-hospital mortality risk"],
        "2": ["5.3% in-hospital mortality risk"],
        "3": ["10.3% in-hospital mortality risk"],
        "4": ["16.5% in-hospital mortality risk"],
        "5": ["24.5% in-hospital mortality risk"]
      },
      "notes": [
        {
          "type": "unordered-list",
          "content": [
            "AIMS65 Score can be used to determine the risk of in-hospital mortality for patients wiht acute upper GI bleeding",
            "The score was derived retrospectively by Saltzman et al in a 2011 study from a population of >29K patients from 187 hospitals who were admitted with acute upper GI bleeding from 2004-2005 ",
            "The AIMS65 score is superior to the Glasgow-Blatchford Score in predicting mortality but the GBS is superior in predicting need for transfusion (Hyett 2013)",
            "Validation studies (Robertson 2016) demonstrate that the AIMS65 score is superior to the Glasgow-Blatchford and Pre-endoscopy Rockall Score for predicting in-hospital mortality, ICU admission and length of stay"
          ]
        }
      ],
      "references": [
        {
          "type": "ordered-list",
          "content": [
            "Saltzman JR, Tabak YP, Hyett BH, Sun X et al. A simple risk score accurately predicts in-hospital mortality, length of stay and cost in acute upper GI bleeding. Gastroinste Endosc. 2011;74:1215-1224",
            "Robertson M, et al. Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. Gastrointestinal Endosc. 83.6(2016):1151-1160",
            "Thandassery RB, Sharma M, John AK, et al. Clinical Application of AIMS65 Scores to Predict Outcomes in Patients wiht Upper Gastrointestinal Hemorrhage. Clinical Endoscopy. 2015;48(5):380-384."
          ]
        }
      ]
    },
    {
      "id": "lower-gi-bleeding-risk-severe-bleeding",
      "title": "Lower GI Bleeding and Risk of Severe Bleeding",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label": "Pulse ≥100bpm",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Systolic Blood Pressure ≤115mmHg",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient had associated syncope",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Blood per rectum during first 4h of evaluation",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient on aspirin",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Patient has ≥3 comorbid conditions",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": ["Risk of Severe Bleeding: 9%"],
        "1 - 3": ["Risk of Severe Bleeding: 43%"],
        "4 - 6": ["Risk of Severe Bleeding: 84%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Strate LL, Orav EJ, Syngal S. Early predictors of severity in acute lower intestinal tract bleeding. Arch Intern Med. 2003; 163: 838-43."
        ]
      }
    },
    {
      "id": "pancreatitis-prognosis-criteria-disease-gallstones",
      "title": "Pancreatitis Prognosis Criteria When Disease Due to Gallstones",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria at time of patient admission:",
          "data": [
            {
              "type": "checkbox",
              "label": "Age >70yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Glucose > 220 mg/dL",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "WBC > 18,000",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "AST > 250",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "LDH > 400",
              "points": "1"
            }
          ]
        },
        {
          "group": "Criteria that may develop over first 2 hospital days:",
          "data": [
            {
              "type": "checkbox",
              "label": "BUN rises >2mg/dL",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Base deficit >5",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Hct drop ≥10% ",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Calcium < 8mg/dL",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "Fluid sequestration >4L",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0 - 2": ["Pancreatitis Mortality Risk is 1.8%"],
        "3 - 4": ["Pancreatitis Mortality Risk is 11%"],
        "5 - 6": ["Pancreatitis Mortality Risk is 33%"],
        "7 - 10": ["Pancreatitis Mortality Risk is almost 100%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Ranson JH, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gyne Ob. 143:209, 1976.",
          "Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. Am J Gastroenterol. 1982 Sep;77(9):633-8."
        ]
      }
    },
    {
      "id": "breast-cancer-recurrence-risk-after-mastectomy",
      "title": "Breast Cancer Recurrence Risk After Mastectomy",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Grade of tumor",
          "data": {
            "type": "radio",
            "options": "I | II | III",
            "points": "6/12/18"
          }
        },
        {
          "group": "Lymph nodes",
          "data": {
            "type": "radio",
            "options": "Negative | Positive",
            "points": "6/12"
          }
        },
        {
          "group": "Lymphatic or Vascular Invasion",
          "data": {
            "type": "radio",
            "options": "No | Present",
            "points": "4/8"
          }
        }
      ],
      "results": {
        "16": ["Recurrence risk of 8.5%"],
        "20": ["Recurrence risk of 12.5%"],
        "22": ["Recurrence risk of 15.8%"],
        "26": ["Recurrence risk of 10%"],
        "28": ["Recurrence risk of 15.5%"],
        "32": ["Recurrence risk of 33%"],
        "34": ["Recurrence risk of 38.5%"],
        "38": ["Recurrence risk of 48%"]
      },
      "notes": {
        "type": "unordered-list",
        "content": [
          "In this study, 23% of all patients developed a local recurrence of breast cancer"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "O'Rourke S, Galea MH, Morgan D, et. al. Local recurrence after simple mastectomy. Br J Surg. 1994 Mar;81(3):386-389."
        ]
      }
    },
    {
      "id": "pneumonia-risk-post-operative-period-non-cardiac-surgery",
      "title": "Pneumonia Risk in Post Operative Period of Non-Cardiac Surgery",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria:",
          "data": [
            {
              "type": "checkbox",
              "label": ">10% weight loss over 6 months",
              "points": "7"
            },
            {
              "type": "checkbox",
              "label": "History of COPD",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": "General anesthetic used",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": "Sensorium impariment",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": "History of CVA",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": ">4 units blood transfusion",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "Emergency operation",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "History of chronic corticosteroid use",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label": "History of smoking within 1 year",
              "points": "3"
            },
            {
              "type": "checkbox",
              "label":
                "History of alcohol use (>2 drinks/day within last 2 weeks)",
              "points": "2"
            }
          ]
        },
        {
          "group": "Type of Surgery",
          "data": [
            {
              "type": "checkbox",
              "label": "AAA repair",
              "points": "15"
            },
            {
              "type": "checkbox",
              "label": "Thoracic surgery",
              "points": "14"
            },
            {
              "type": "checkbox",
              "label": "Upper abdominal surgery",
              "points": "10"
            },
            {
              "type": "checkbox",
              "label": "Neck surgery",
              "points": "8"
            },
            {
              "type": "checkbox",
              "label": "Neurosurgery",
              "points": "8"
            },
            {
              "type": "checkbox",
              "label": "Vascular surgery",
              "points": "3"
            }
          ]
        },
        {
          "group": "Patient Age",
          "data": [
            {
              "type": "checkbox",
              "label": ">80 years",
              "points": "17"
            },
            {
              "type": "checkbox",
              "label": "70-79 years",
              "points": "13"
            },
            {
              "type": "checkbox",
              "label": "60-69 years",
              "points": "9"
            },
            {
              "type": "checkbox",
              "label": "50-59 years",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": "<50 years",
              "points": "0"
            }
          ]
        },
        {
          "group": "Patient's Functional status",
          "data": [
            {
              "type": "checkbox",
              "label": "Dependent",
              "points": "10"
            },
            {
              "type": "checkbox",
              "label": "Partially dependent",
              "points": "6"
            },
            {
              "type": "checkbox",
              "label": "Independent",
              "points": "0"
            }
          ]
        },
        {
          "group": "BUN concentration",
          "data": [
            {
              "type": "checkbox",
              "label": "< 8mg% (2.86 mmol/L)",
              "points": "4"
            },
            {
              "type": "checkbox",
              "label": "22-29 mg% (7.85-10.6 mmol/L)",
              "points": "2"
            },
            {
              "type": "checkbox",
              "label": "≥ 30mg% (10.7 mmol/L)",
              "points": "3"
            }
          ]
        }
      ],
      "results": {
        "0 - 15": ["Risk of pneumonia 0.24%"],
        "16 - 25": ["Risk of pneumonia 1.19%"],
        "26 - 40": ["Risk of pneumonia 4%"],
        "41 - 55": ["Risk of pneumonia 9.4%"],
        "56 - 84": ["Risk of pneumonia 15.8%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Arozullah AM, Khuri SF, Henderson WG, et. al. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery. Ann Intern Med. 2001 Nov 20;135(10):847-57."
        ]
      }
    },
    {
      "id": "bleeding-risk-major-complication-warfarin-therapy",
      "title": "Bleeding Risk (Major Complication) on Warfarin Therapy",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Age ≥60yrs",
              "points": "1.6"
            },
            {
              "type": "checkbox",
              "label": "Malignancy Present",
              "points": "2.2"
            }
          ]
        },
        {
          "group": "Age",
          "data": {
            "type": "radio",
            "options": "Female/Male",
            "points": "1.3/0"
          }
        }
      ],
      "results": {
        "0": ["Risk of any bleeding complications: 0-1%"],
        "1.3 - 3": ["Risk of any bleeding complications: 1-2%"],
        "3.1 - 5.1": ["Risk of any bleeding complications: 7-14%"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999; 159: 457-60."
        ]
      }
    },
    {
      "id": "bleeding-risk-index-warfarin-therapy",
      "title": "Bleeding Risk Index for Warfarin Therapy",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Criteria",
          "data": [
            {
              "type": "checkbox",
              "label": "Patient Age ≥65yrs",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of CVA",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label": "History of GI bleeding",
              "points": "1"
            },
            {
              "type": "checkbox",
              "label":
                "Recent Myocardial Infarction, Anemia with HCT <30%, Creatinine 1.5 or Diabetes",
              "points": "1"
            }
          ]
        }
      ],
      "results": {
        "0": ["Risk of Major Bleeding: 2% @ 3 months, 3% at 12 months"],
        "1 - 2": ["Risk of Major Bleeding: 5% @ 3 months, 12% at 12 months"],
        "3 - 4": ["Risk of Major Bleeding: 23% @ 3 months, 48% at 12 months"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for DVT and PE. Arch Intern Med. 2003; 163: 917-20.",
          "Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998 Aug;105(2):91-99."
        ]
      }
    },
    {
      "id": "myelodysplastic-syndrome-international-prognostic-scoring-system",
      "title":
        "Myelodysplastic Syndrome International Prognostic Scoring System",
      "type": "points",
      "points": 0,
      "questions": [
        {
          "group": "Percentage of Bone Marrow Blasts",
          "data": {
            "type": "radio",
            "options": "<5% | 5-10% | 11-20% | 21-30%",
            "points": "0/0.5/1.5/2"
          }
        },
        {
          "group": "Karyotype",
          "data": {
            "type": "radio",
            "options":
              "Normal, Y-, 5q-, 20q- | Abnormal chromosome 7 or ≥3 more abnormalities | All other cytogenic abnormalities ",
            "points": "0/1/0.5"
          }
        },
        {
          "group":
            "Cytopenias (Hemoglobin <10g/dL, ANS < 1,800/µL, Platelet count < 100,000/µL",
          "data": {
            "type": "radio",
            "options":
              "No cytopenia/Cytopenia of 1 cell type | Cytonpenia of 2 or 3 cell types",
            "points": "0/0.5"
          }
        }
      ],
      "results": {
        "0": ["Prognostic Score: Low (Median survival of 5.7 years)"],
        "0.5 - 1": [
          "Prognostic Score: Intermediate 1 (Median survival of 3.5 years)"
        ],
        "1.5 - 2": [
          "Prognostic Score: Intermediate 2 (Median survival of 1.2 years)"
        ],
        "2.5 - 3.5": ["Prognostic Score: High (Median survival of 0.4 years)"]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Greenberg P, Cox C, LeBeau MM et. al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood. 1997; 89;6: 2079 - 2088. Erratum in Blood 1998; 91:1100.",
          "Greenberg P, Cox C, LeBeau MM et. al. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. Blood. 1997; 89;6: 2079 - 2088. Erratum in Blood 1998; 91:1100."
        ]
      }
    },
    {
      "id": "creatinine-clearance-cockcroft-gault",
      "title": "Creatinine Clearance Cockcroft Gault",
      "type": "formula",
      "questions": [
        {
          "group": "Gender",
          "data": [
            {
              "type": "radio",
              "options": "Male | Female",
              "points": "1/0.85"
            }
          ]
        },
        {
          "group": "Patient's Age",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Age",
              "values": ["yr", "mo"]
            }
          ]
        },
        {
          "group": "Serum Creatinine",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Serum Creatinine",
              "values": ["mg/dL", "mg/mL", "mg%", "gm/dL", "gm/L"]
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Weight",
              "values": ["kg", "lb"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Weight is the estimated lean body weight of the patient. Default unit for weight is kg.",
          "This calculator provides an estimate of the creatinine clearance if patient's plasma creatinine concentration is stable"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41."
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": [
          "CreatClear = Sex ⨉ ((140-Age)/(Serum Creatinine))⨉(Weight/72)"
        ]
      }
    },
    {
      "id": "oxygen-content-venous-blood",
      "title": "Oxygen Content of Venous Blood",
      "type": "formula",
      "questions": [
        {
          "group": "Hemoglobin (Hgb)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Hgb",
              "values": ["mg/dL", "g/dL", "g/L", "mcg/dL", "mcg/mL", "mg%", "mg/mL", "ng/mL"]
            }
          ]
        },
        {
          "group": "Venous Oxygen Saturation",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter O2vSat",
              "values": ["%", "fraction", "ratio"]
            }
          ]
        },
        {
          "group": "Partial Pressure of Oxygen in Venous Blood (PvO2)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter PvO2",
              "values": ["mmHg", "psi", "atm", "Pa", "torr"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Calculates patient venous blood oxygen content"
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": [
          "CvO2 = ( Hgb ⨉ 13.4 ⨉ O2vSat / 100 ) + ( PvO2 ⨉ 0.031 )"
        ]
      }
    },
    {
      "id": "dose-adjustment-body-surface-area",
      "title": "Dose Adjustment for Body Surface Area",
      "type": "formula",
      "questions": [
        {
          "group": "Standard dose",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter dose",
              "values": ["mg", "g", "mcg"]
            }
          ]
        },
        {
          "group": "Height",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter height",
              "values": ["cm", "m", "in"]
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter weight",
              "values": ["kg", "lb"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Calculates the adjusted dose based on the DuBois method for body surface area (BSA)"
        ]
      },
      "formula": {
        "type": "unordered-list",
        "content": [
          "BSA = 0.007184 ⨉ Height^0.725 ⨉ Weight^0.425",
          "AdjustedDose = StandardDose * BSA / 1.73"
        ]
      }
    },
    {
      "id": "oxygen-content-arterial-blood",
      "title": "Oxygen Content of Arterial Blood",
      "type": "formula",
      "questions": [
        {
          "group": "Hemoglobin (Hgb)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Hgb",
              "values": ["mg/dL", "g/dL", "g/L", "mcg/dL", "mcg/mL", "mg%", "mg/mL", "ng/mL"]
            }
          ]
        },
        {
          "group": "Oxygen Saturation (O2Sat)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter O2Sat",
              "values": ["%", "fraction", "ratio"]
            }
          ]
        },
        {
          "group": "Partial Pressure of Oxygen in Arterial Blood (PaO2)",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter PaO2",
              "values": ["mmHg", "psi", "atm", "Pa", "torr"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Calculates patient arterial blood oxygen content"
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": [
          "CaO2 = ( Hgb ⨉ 13.4 ⨉ O2Sat / 100 ) + ( PaO2 ⨉ 0.031 )"
        ]
      }
    },
    {
      "id": "estimated-blood-volume",
      "title": "Estimated Blood Volume",
      "type": "formula",
      "questions": [
        {
          "group": "Average Blood Volume",
          "data": [
            {
              "type": "radio",
              "options": "Male | Female | Infants | Neonates | Premature Neonates",
              "points": "75/65/80/85/96"
            }
          ]
        },
        {
          "group": "Weight",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter Weight",
              "values": ["kg", "lb", "g", "mg"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "This calculator provides an estimate of blood volume for different patient weights and average blood volumes",
          "Average blood volume values are given in mL/kg for the different patient groups. Numbers next to each patient group represent the values that are used. For example average blood volume for Males is 75mL/kg"
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Morgan, Mikhail, and Murray. Clinical Anesthesiology. 3rd Edition."
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": [
          "Blood Volume = Weight ⨉ Average Blood Volume "
        ]
      }
    },
    {
      "id": "sodium-correction-hyperglycemia",
      "title": "Sodium Correction in Hyperglycemia",
      "type": "formula",
      "questions": [
        {
          "group": "Measured Na",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter sodium value",
              "values": ["mEq/L", "mmol/L"]
            }
          ]
        },
        {
          "group": "Glucose",
          "data": [
            {
              "type": "input/select",
              "placeholder": "Enter glucose value",
              "values": ["mmol/L", "mg/dL", "mg%", "g/L", "g/dL","mcg/dL", "mcg/mL"]
            }
          ]
        }
      ],
      "results": {},
      "notes": {
        "type": "unordered-list",
        "content": [
          "Calculates the actual sodium level in patients with hyperglycemia based on Katz's sodium factor",
          "The corrected sodium factor in the 1976 Katz publication was 1.6 mEq/L. However, in 1999 Hillier et. al evaluated 6 healthy subjects, induced hyperglycemia and measured actual sodium levels. They found that a sodium correction factor of 2.4 mEq/L was more accurate."
        ]
      },
      "references": {
        "type": "ordered-list",
        "content": [
          "Katz MA. Hyperglycemia-induced hyponatremia calculation of expected serum sodium depression. N Engl J Med. 1973 Oct 18;289(16):843-4.",
          "Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999 Apr;106(4):399-403."
        ]
      },
      "formula": {
        "type": "paragraph",
        "content": [
          "Na = MeasuredSodium + 0.016 ⨉ (Glucose - 100)"
        ]
      }
    }
  ]
}
